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INTRODUCTION 
Dendrimers are class of well defined hyperbranched 
synthetic polymer systems, which can be conjugated to 
various chemical species, such as detection agents, imaging 
agents, targeting components, biomolecules, 
pharmaceutical/ therapeutic agents, radio ligands, affinity 
ligands, for various bioanalytical applications.  
The term “Dendrimer” arise from two Greek words; 
“Dendron” meaning tree and “Meros” meaning part. A 
typical dendrimer structure consists of three basic 
components: a multi-functional central core moiety where 
other molecules can be trapped 
1, 2
, branched units that 
emanates from the central core and external capping-
groups. The highly regular branching units are organized in 
layers called “generations”, and represent the repeating 
monomer unit of these synthetic macromolecules
3
. 
Therefore, dendrimers can be synthesized from simple 
branched monomer units, in a precise and controlled 
fashion from trunk to branch and to leaf “surface groups”. 
The three-dimensional structure of dendrimers gives them a 
variety of unique properties, such as nanoscaled globular 
shape, well-defined functional groups at the periphery, 
hydrophobic or hydrophilic cavities in the interior and 
extremely low polydispersity 
4
, and thus a wide range of 
potential applications. 
Dendrimer is a nanoparticle and so has advantages over 
microparticles or others due to its small size, easy uptake 
by cells (through endocytosis)
 4, 5
. They are branched 
macromolecules have a central core unit having a high 
degree of molecular uniformity, narrow molecular weight, 
distribution, specific size and shape characteristics, and a 
highly- functionalized, terminal surface. The manufacturing 
process is a series of repetitive steps generating shells, 
starting with a central initiator core. Each subsequent shell 
represents a new "generation" of polymer with a larger 
molecular diameter, twice the number of reactive surface 
sites, and approximately double the molecular weight of the 
preceding generation. Dendrimers have cellular uptake 
through endocytosis and thus brings drug “bound” to 
dendrimers into the cell.  
ABSTRACT: 
This review gives concise information about the dendrimers, properties, synthesis and application in drug delivery, diagnosis and 
therapy. Due to their unique architecture these have improved physical and chemical properties. They show high solubility, miscibility 
and reactivity due to their terminal groups. Dendrimers have well defined size, shape, molecular weight and monodispersity. These 
properties make the dendrimers a suitable carrier in drug delivery application. Dendrimers are unimolecular miceller in nature and due 
to this enhances the solubility of poorly soluble drugs. Their compatibility with DNA, heparin and polyanions make them more 
versatile. Dendrimers, also referred as modern day polymers, they offer much more good properties than the conventional polymers. 
Due to their multivalent and mono disperse character dendrimers have stimulated wide interest in the field of chemistry biology, 
especially in applications like drug delivery, gene therapy and chemotherapy. Self assembly produces a faster means of generating 
nanoscopic functional and structural systems. But their actual utility in drug delivery can be assessed only after deep understanding of 
factors affecting their properties and their behavior in vivo. 
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Figure 1: Schematic representation of the Dendrimer 
Structure 
The precise control over the distribution of drugs is 
highly valuable to abolish the typical drawbacks of 
traditional medicine. In recent years, improved 
pharmacokinetics, biodistribution and controlled release 
of the drug to the specific targeted site has been 
achieved with polymer based drug delivery
6
 Unlike 
traditional polymers, dendrimers have received 
considerable attention in biological applications due to 
their high water solubility,
7
 biocompatibility,
8
 
polyvalency
9
 and precise molecular weight.
3
 These 
features make them an ideal carrier for drug delivery and 
targeting applications. For investigating dendrimers as 
drug delivery vehicles, their biopermeability across the 
biological membranes should be considered.  
In this review, we report on the noteworthy scientific 
advances and most recent literature, dealing with the 
properties, their advantage over conventional linear 
polymers and their application in drug delivery, 
diagnosis and therapy. 
 
Table 1: Various Dendrimer based products 
Name of Product Type Company Use Status Ref 
Vivagel  Poly‑L‑lysine Starpharma Prevention of HIV infection Clinical trials 
(Phase 3) 
9 
Priostar  PEHAM/PEA 
 
Starpharma  Targeted diagnostic and 
therapeutic delivery for cancer 
Marketed 10, 11 
Starburst PAMAM Dow chemical Targeted diagnostic and 
therapeutic delivery for cancer 
Marketed 12 
Stratus CS  PAMAM Dade Behring Cardiac marker Marketed 13 
Astramol® PPI Starpharma  - Marketed 14 
Taxotere  ND Sanofi Aventis Anticancer drug delivery - - 
SuperFect  PAMAM Qiagen Gene transfection Marketed 15,16 
Alert ticket  PAMAM US Army 
Research Lab. 
Anthrax detection Marketed 17 
Dendrimer‑docetaxel  ND Starpharma Breast cancer treatment Preclinical 18 
Dendrimer‑oxaliplatin ND Starpharma Colon cancer treatment Preclinical 18 
ND: not define, PEHAM: Poly (etherhydroxylamine), PEA: Poly (esteramine), PAMAM: Polyamidoamine, PPI: Poly (propylene 
imine), HIV: Human immunodeficiency virus, STDs: Sexually transmitted diseases 
 
WHAT MAKES DENDRIMERS SPECIAL IN DRUG 
DELIVERY 
Dendrimers are dentritic polymers that have very well-
defined nanostructures and high level control over its size, 
branching density and surface functionality. They are 
useful nanoscale carriers for drug and gene delivery. Both 
hydrophilic and phrophobic drug molecules can be 
formulated with dendrimers. They have been applied in 
intravenous, oral, pulmonary, nasal, ocular, and 
transdermal drug delivery systems. 
Dendrimers have shown enormous potential as 
nanocarrier/delivery systems because they can cross cell 
barriers by both paracellular and transcellular pathways. 
The ability to statistically modify and optimize the number 
and/or ratio of dendrimer surface groups that influence 
biodistribution, receptor-mediated targeting, therapy 
dosage or controlled release of drugs from the dendrimer 
interior.  
The three-dimensional structure of dendrimers gives them a 
variety of unique properties, such as nanoscaled globular 
shape, well-defined functional groups at the periphery, 
hydrophobic or hydrophilic cavities in the interior and 
extremely low polydispersity 
19
, and thus a wide range of 
potential applications. For example, most dendrimers have 
globular structures with molecular diameters less than 10 
nm, which can be modulated by varying dendrimer 
generations. 
This property gives dendrimers similar sizes and shapes as 
specific proteins and other biomolecules and thereby makes 
them perfect as biomimics 
20
. Also, the highly regular 
branching pattern of dendrimers imbues these dendritic 
architectures with well-defined numbers of periphery 
functional groups, providing opportunities for the presence 
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of drug molecules, targeting moieties, and solubilizing 
groups on the surface in a multivalent fashion 
21, 22
. 
Moreover, hydrophobic and hydrophilic cavities in the 
interior of dendrimers make them useful candidates as 
unimolecular micelles for the encapsulation of guest 
molecules, especially drugs 
23–24
. Finally, the low 
polydispersity of dendrimers assures the reproducibility of 
biodistribution of polymeric prodrugs using them as 
scaffolds 
25, 26
. 
Nanoparticles having a size in the range 1–10 nm have the 
capacity to diffuse into tumor cells. This helps to overcome 
limitations relating to chemotherapy using free drug such 
as poor in vivo/in vitro correlation and overcome other 
possible resistances offered by tumors. 
Dendrimers are one of the most useful non-viral gene 
delivery systems. Their ability to transfect cells without 
inducing toxicity and be tuned for stimuli-induced gene 
delivery confers a great advantage over other gene delivery 
vectors for use in vivo. 
The well-defined hyperbranched structure of dendrimers 
has motivated chemists to explore the possibility for 
mimicking protein functions with dendritic 
macromolecules, such as O2-carrying haemoproteins and 
coenzyme B12. Thus, dendrimers can be tuned for: (i) be 
stimuli-responsive nanocarriers, (ii) include moleculartags, 
(iii) possess high payload efficiency, (iv) decrease dosage 
requirements as well as re-dosage frequency and (v) target 
delivery and minimize drug migration, thus suppressing 
secondary effects during drug treatment. 
The interesting nanoscale architecture of dendrimers 
confers several structural benefits over linear polymers, 
larger nanoparticles and liposomes. Such advantages 
include rapid cellular entry, reduced macrophage uptake, 
targetability and more facile passage across biological 
barriers by transcytosis
27
. In comparison to linear polymers, 
dendrimers are multivalent owing to the presence of high 
multiplicities of reactive surface end groups, making them 
ideal drug carriers with higher drug payload capacities
28
. 
Encapsulation of drugs in PEGylated dendrimers can lead 
to enhanced permeation and retention (EPR) of the drug. 
To briefly reiterate, properties of dendritic polymers 
important for drug delivery include negligible 
polydispersity, a high-density payload of pro-drug, and the 
ability to selectively release the active form of drug 
precisely at its intended site of action. Therefore, detailed 
in vivo toxicity examination of dendrimers is important and 
can facilitate the design of tailored dendrimer-mediated 
CNS drug-delivery systems. 
They can be synthesized and designed for specific 
applications. Due to their feasible topology, functionality 
and dimensions, they are ideal drug delivery systems; and 
also, their size is very close to various important biological 
polymers and assemblies such as DNA and proteins which 
are physiologically ideal
.29-30
 
The covalent attachment of drugs to the surface groups of 
dendrimers through hydrolysable or biodegradable linkages 
enhances the pharmacological properties of the drug and 
offers the opportunity for a greater control over drug 
release. 
 
 
 
ADVANTAGES OF DENDRIMERS 
The following properties of the dendrimers make them as 
an ideal carrier for drug delivery, therapy and diagnosis.  
1. Low polydispersity index: 
They have lower polydispersity index, due to stringent 
control during synthesis. As the density of branches 
increases the outer most branches arrange themselves 
surrounding a lower density core in the form of spheres and 
outer surface density is more and most of the space remains 
hollow towards core. This region can be utilized for 
entrapment of variety of drugs
29 
2. Enhanced permeability and retention effect 
Size of dendrimers i.e. (Generation 4-4.4 nm) is in nano 
range. Cancer cells have leaky membranes and having 
higher biopermeability for anticancer drugs. Dendrimers 
might show an enhanced permeability and retention effect 
(depending on their M.W) that allows them to target tumor 
cells more effectively than small molecules. Lymphatic 
system is one way and drug loaded dendrimers may get 
retained inside 
31
.  
3. High permeability 
This property improves intracellular trafficking of drugs. 
Dendrimers can cross biobarriers like blood brain barrier, 
cell membrane. Nanometre range and uniformity in size 
enhance their ability to cross cell membranes and 
diminishes the risk of undesired clearance from the body 
through the liver or spleen 
32-33
.  
4. Sustained /extended effect  
Dendrimers releases drug in a sustained manner. PAMAM 
dendrimers exhibited slower release, higher accumulation 
in solid tumors, and lower toxicity. Conjugation with 
Polyethylene glycol on the surface of these nanocarriers 
avoids non-specific interaction with plasma proteins or 
engulfment. Increase in blood circulation time is essential 
to achieve desired clinical effect 
34
.  
5. Higher Solublization Potential  
Ionic interaction, hydrogen bonding and hydrophobic 
interactions are probable mechanism by which dendrimers 
show its solubility enhancing property. Most anticancer 
drugs have poor solubility and can be loaded into 
dendrimers to improve solubility 
35-36
. Dendrimers are 
capable of improving the solubility, biodistribution, and 
efficacy of a number of therapeutics as well as being used 
as imaging and diagnostic molecules in animal models 
bearing brain tumors. 
6. High uniformity and purity  
The synthetic process used produces dendrimers with 
uniform sizes range, well defined surface functionality, and 
negligible impurity. Monodispersed dendrimers would 
facilitate us to attain targeted drug delivery 
37, 38
.  
7. Multifunctional platform 
Multiple functional groups are present on outer surface of 
dendrimers, which can be used to attach vector devices for 
targeting to particular site in the body. Terminal groups 
may also be modified to reorganize specific receptors. The 
surface modification may allow designing dendrimers 
mimicking biological exo-receptors, substrates, inhibitors 
or cofactors. Free surface groups can form complex or 
conjugates with drug excellent molecules or ligands by 
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using cross linking agents. The surface of dendrimers may 
be conjugated with ligands, solubility modifiers, and stealth 
molecules 
21,39
.  
8. High loading capacity 
Dendrimers structures can be used to load and store a wide 
range of organic or inorganic molecules by encapsulation 
and absorption on surface. Drug can get entrapped inside 
the internal cavities as well as electro statically in the 
surface of dendrimers 
40
.  
9. High stability  
Dendrimers drug complex or conjugate shows better 
colloidal, biological and shelf-stability. Dendrimers have 
nanoscopic particle size range from 1 - 100 nm, which 
makes them less susceptible for reticulum endothelium 
uptake.  
10. Low toxicity 
Most dendrimers systems display very low cytotoxicity 
levels but have good biodegradability 
24
. PEGylation of the 
dendrimer surface can prolong its circulation time and 
reduce its toxicity 
11. Low immunogenicity 
Dendrimers shows low or negligible immunogenic 
response when injected or used topically 
41
. The problems 
in vesicular system like chemical instability, drug leakage, 
aggregation and fusion during storage, solubility in 
physiological environment, lysis of phospholipids, purity of 
natural phospholipids lack in dendritic system 
12. Dendrimers can be modified as stimuli responsive to 
release drug. The similarity of dendrimers structure 
with IgM antibodies (pentamers radially distributed) 
suggest that they may be used to function as antibodies 
e.g. activation of macrophages, recognition, and high 
affinity to antigen.  
 
MAJOR CHALLENGES AND WAYS TO 
OVERCOME 
Despite these promising results, this field is still in its 
infancy. It is known that the dendrimers may have toxicity 
mainly attributed to the interaction of the cationic 
dendrimers surface with negative biological load 
membranes damaging cellular membranes causing 
hemolytic toxicity and cytotoxicity.  
1. Toxicity 
A basic issue in drug delivery is the avoidance of non-
specific, systemic, or off target toxicity. Appropriate 
modifications of the dendrimers surface can greatly reduce 
their toxicity.
42 
Such modified dendrimers can be used in 
nanomedical applications, as they possess the advantage of 
dendrimers spatial structure and simultaneously possess 
reduced toxic activity. Therefore, PAMAM dendrimers are 
more cationic than anionic cytotoxic. An example of 
interaction with lipid bilayers of cells occurs with the 
cationic dendrimer-G7 PAMAM which comes to form 
holes 15-40 nm in diameter, which disturbs the flow of 
electrolyte causing cell death. 
To overcome the problem of toxicity the group of Michal 
Ciolkowski and Johannes F. Petersen has done surface 
modification of polyamidoamine (PAMAM) dendrimer of 
the fourth generation (G4). The amine surface groups of a 
G4 PAMAM-NH2 dendrimer were transformed into 
pyrrolidone derivatives by means of reaction with dimethyl 
itaconate. The researchers reported reduced toxicity 
through interaction studies with human serum albumin 
(HSA), influence on viability of mouse neuroblastoma 
(N2a) cell line, as well as through hemolytic activity.
43
 
PEGylation of the dendrimer surface can prolong its 
circulation time and reduce its toxicity. BBB- or CNS-
targeting ligand modification of the dendrimer surface can 
improve the rate and duration of drug delivery to brain 
tumor cells prior to the clearance of the remaining drug-
delivery system. Imaging and diagnostic agents 
incorporated into dendrimers can help with the evaluation 
of brain tumors and dendrimer-associated CNS toxicity. 
However, challenges still exist regarding the deeper 
toxicological studies, specific targeting, and noninvasive 
alternative drug administration methods. The ultimate goal 
of dendrimer-mediated CNS drug-delivery systems is to 
engineer the dendrimers to be safe and to enable their 
longterm use without the accumulation of adverse effects. 
Many toxic effects of dendrimers are attenuated at their 
surfaces with hydrophilic molecules and poly (ethylene 
glycol) (PEG) which masks the surface charge cationic 
dendrimers improving biocompatibility and increasing the 
solubility of the polymers. The pegylated dendrimers have 
lower cytotoxicity and longer stay in the blood than non-
pegylated dendrimers. PEGylation increases the physical 
dendrimers size which reduces renal clearance
44-45
 
BBB- or CNS-targeting ligand modification of the 
dendrimer surface can improve the rate and duration of 
drug delivery to brain tumor cells prior to the clearance of 
the remaining drug-delivery system. Imaging and 
diagnostic agents incorporated into dendrimers can help 
with the evaluation of brain tumors and dendrimer-
associated CNS toxicity. However, challenges still exist 
regarding the deeper toxicological studies, specific 
targeting, and a noninvasive alternative drug administration 
method. The ultimate goal of dendrimer-mediated CNS 
drug-delivery systems is to engineer the dendrimers to be 
safe and to enable their longterm use without the 
accumulation of adverse effects. 
2. Water Solubility and Immunogenicity 
There are two biocompatibility issues presents in 
dendrimers, namely water solubility and immunogenicity, 
are closely related insofar as highly-hydrated 
macromolecules tend to be less immunogenic. With 
dendrimers, there are many options available to overcome 
difficulties that arise in these areas. For example, solubility 
can be readily adjusted by surface modifications to surface 
chemistry or by the addition of conjugated ligands. 
Moreover, dendrimers such as the commonly used G3, G5, 
and G7 PAMAM clusters are not inherently immunogenic 
46
. Derivatized PAMAM such as the G4D-(1B4M-Gd)62 
magnetic resonance imaging (MRI) contrast dendrimer, 
however, can become immunogenic (which is not 
surprising considering the deliberate efforts to render small 
molecules immunogenic through presentation on a 
dendritic scaffold). This problem once again tying together 
the concepts of solubility and immunity – was overcome in 
one study by conjugation of poly(ethylene glycol) (PEG) to 
the surface of the dendrimer. Notably, PEG also had the 
positive effect of decreasing non-specific clearance from 
the blood, likely due to the increased hydration and 
resulting solubility of the particle 
47
. 
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PROPERTIES OF DENDRIMERS  
1. Monodispersivity, size and shape  
The monodispersion means that the dendrimers has a well 
defined molecular structure and without large individual 
variations, in other words, they are homogeneous unlike 
other polymers due to their controlled synthesis and 
purification processes.  
Dendrimers are monodisperse in nature i.e. they have 
isomolecular species, whose molecular size, shape and 
disposition of organic moieties are adjusted and controlled 
57
. Such control facilitates the research, because it becomes 
a tool with defined size ranges 
58
. The advantage of low 
polydispersity makes it possible to predict the 
pharmacokinetic behavior of dendrimers because little 
variation of molecules weight makes it possible to know 
the sample movements of these polymers for biological 
organism 
59
. Dendrimers shows improved physical and 
chemical properties due to their molecular architecture. The 
dendrimers shape depend on the generation i.e. lower 
generation shows open planar elliptical shape while higher 
generation shows compact-spherical shape 
60
.  
Due to their nanometric scales and other properties that are 
similar to proteins, dendrimers are also known as artificial 
proteins and gain attention in studies that make use of their 
biomimetic properties. The dendrimer can be controlled by 
molecular engineering so that its size resembling to 
antibodies, enzymes and globular proteins
61-63
.  
2. Polivalency  
Polyvalency is useful as it provides for versatile 
functionalization; it is also extremely important to produce 
multiple interactions with biological receptor sites, for 
example, in the design of antiviral therapeutic agents. The 
polivalency is related to the quantity of reactive sites on 
outside of the dendrimer potential to form connections with 
various materials of interest 
64
. Areas of high multivalent 
dendrimers of generations can contain a large number of 
functional groups. This makes the surface of the dendrimer 
branches and more susceptible to interactions with a large 
number of species. The multivalencyallows better 
interaction with biological targets since most of the 
molecular interactions occur through biological multivalent 
bonds. The valency binder is the number of links that can 
be established with a receiver or receivers. The strength of 
multivalent interactions exceeds the sum of the forces. 
Dendrimers as potential platform in nanotechnology-based 
drug delivery systems exhibit higher biological activity 
compared to conventional drug molecules because the 
dendrimer can react with multiple receivers at once in the 
biological site of action 
65
.  
3. Solubility and biocompability  
Surface groups of the dendrimers play an important role in 
the solubility of dendrimers. Dendrimers generally have 
greater solubility in common solvents as compared to linear 
polymers. However, the solubility depends on various 
components in addition to the surface groups as the 
generation number, nature of repeating units and even the 
core. What enables the construction of dendrimers perfectly 
soluble in a large number of solvents, ensuring both the 
solubility of dendrimers in organic solvents, which leads a 
rapid dissolution in water and enhances the activity of 
hydrophobic molecules 
62
.  
If the surface end groups are hydrophobic in nature, then 
dendrimers are soluble in nonpolar solvent. If the surface 
end groups are hydrophilic in nature and dendrimers are 
soluble in polar solvent. The high solubility, miscibility and 
reactivity and binding capacity of dendrimers is due to the 
presence of many chain end groups 
60,66,67
. PAMAM 
dendrimers have received considerable attention because its 
ability to solubilize water-insoluble drugs and transporting 
them through the biomembranes, increasing the 
bioavailability of these drugs 
68, 69
.  
Before being used as biological agents in drug delivery, 
dendrimers should meet a variety of requirements such as: 
(1) having no toxicity, (2) is not immunogenic (3) ability to 
cross biological barriers such as the walls and the intestinal 
membranes, (4) remain in circulation long enough to be 
effective clinically (5) ability to deliver specific structures 
70, 71
. The biological properties as, for example, 
immunogenicity and toxicity depends mainly on the size 
and the surface groups of the dendrimers. The interior 
structure therefore has less influence because usually the 
dendrimer interactions occur with the outside via the 
exposed surface groups, which makes the dendrimers able 
to cross cell surfaces.  
4. Toxicity  
It is known that the dendrimers may cause toxicity mainly 
attributed to the interaction of the cationic dendrimers 
surface with negative biological load membranes damaging 
cellular membranes causing hemolytic toxicity and 
cytotoxicity. Therefore, PAMAM dendrimers are more 
cationic than anionic cytotoxic. An example of interaction 
with lipid bilayers of cells occurs with the cationic 
dendrimer-G7 PAMAM which comes to form holes 15-40 
nm in diameter, which disturbs the flow of electrolyte 
causing cell death 
72
. Many toxic effects of dendrimers are 
attenuated at their surfaces with hydrophilic molecules and 
poly (ethylene glycol) (PEG) which masks the surface 
charge cationic dendrimers improving biocompatibility and 
increasing the solubility of the polymers. The pegylated 
dendrimers have lower cytotoxicity and longer stay in the 
blood than non-pegylated dendrimers. PEGylation 
increases the physical dendrimers size which reduces renal 
clearance since the glomerular filtration limit is reached 
73, 
74
.  
5. Interactions of drugs with dendrimers  
The dendrimers designed for drug delivery have the 
intention to improve the pharmacokinetics and 
biodistribution of drugs and may also provide a controlled 
release of the drug with the goal of reaching the target 
tissues 
75
. The strategy of coupling small molecules to 
polymeric scaffolds by covalent linkages to improve their 
pharmacological properties has been under experimental 
test for over three decades 
76, 21
. In most cases, however, the 
conjugated dendritic assembly functions as pro-drug 
‘where, upon internalization into the target cell, the 
conjugate must be liberated to activate the drug. 
Dendrimers interact with drug molecules physically by 
absorption on surface by electrostatic interactions or by 
conjugation with the surface groups for covalent bonding 
or by encapsulation of the drug into the cavities of the 
dendrimer 
D5,77,78
. The technique of drugs encapsulation 
may be a purely physical entrapment or involve 
interactions with specific structures within the dendrimer 
79
. 
Encapsulation is a general strategy for low molecular 
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weight molecules and are transported on the bioactive 
surface of dendrimers induce undesired immunogenicity 
63
. 
Molecular recognition events at dendrimer surfaces are 
distinguished by the large number of often identical end 
groups presented by the dendritic host. When these groups 
are charged, the surface may have as a polyelectrolyte and 
is likely to electrostatically attract oppositely charged 
molecules 
80
. One example of electrostatic interactions 
between polyelectrolyte dendrimers and charged species 
include the aggregation of methylene blue on the dendrimer 
surface and the binding of EPR probes such as copper 
complexes and nitroxide cation radicals 
81
.  
The empty internal cavities generally have hydrophobic 
properties which allow interactions with poorly soluble 
drugs. The existence of atoms of nitrogen and oxygen in 
the internal structure of the dendrimer allows interaction by 
hydrogen bonds with the drug 
62
. The high density of 
functional groups are ionizable at the periphery of the 
dendrimer (such as amines and carboxyl groups) permits to 
fix a large number of ionizable drugs by electrostatic 
interactions and transporting them to their destination. 
Covalent interaction method offers advantages over 
previous methods, therefore allow multiple drugs to be 
attached to each dendrimer through the numerous groups of 
the surface, the covalent bonds between the drug and the 
polymer are likely more difficult to break giving them 
greater control over the drugs, overcoming the force of 
interaction achieved by electrostatic bonds and 
encapsulation 
75
.  
6. Viscosity  
In solution dendrimers form a tightly packed ball which 
influences its rheological properties. The intrinsic viscosity 
dendrimers solution does not exhibit linear relationship 
with mass but it is highest for a specific generation and 
then it begins to decrease.  
7. Self-assembling dendrimers.  
Another fascinating and rapidly developing area of 
chemistry is that of self-assembly. Self-assembly is the 
spontaneous, precise association of chemical species by 
specific, complementary intermolecular forces. Recently, 
the selfassembly of dendritic structures has been of 
increasing interest 
82
. Because dendrimers contain three 
distinct structural parts (the core, end-groups, and branched 
units connecting the core and periphery), there are three 
strategies for self-assembling dendrimers. The first is to 
create Dendrons with a core unit that is capable of 
recognizing itself or a ditopic or polytopic core structure, 
therefore leading to spontaneous formation of a dendrimer 
83
. A self-assembling dendrimer using pseudorotaxane 
formation as the organizing force was reported by Gibson 
and coworkers 
84
. 
 
FACTORS AFFECTING DENDRIMER 
PROPERTIES 
1. Effect of pH 
The study of structural behaviour of PAMAM dendrimers 
as a function of pH, by applying molecular dynamics show 
that the dendrimer has an extended conformation, based on 
a highly ordered structure at low pH (pH<4). At this pH, 
the interior is getting increasingly “hollow” as the 
generation number increases as a result of repulsion 
between the positively charged amines both at the 
dendrimer surface and the tertiary amines in the interior. At 
neutral pH, back-folding occurs which may be a 
consequence of hydrogen bonding between the uncharged 
tertiary amines in the interior and the positively charged 
surface amines. At higher pH (pH>10) the dendrimer 
contract as the charge of the molecule becomes neutral, 
acquiring a more spherical (globular) structure, where the 
repulsive forces between the dendrimer arms and between 
the surface groups reaches a minimum. At this pH, the 
conformation has a higher degree of back-folding as a 
consequence of the weak “inter-dendron” repulsive 
forces
85,86
. 
2. Effect of Solvent 
The solvation power of any solvent to solvate the 
dendrimer is a very important parameter when investigating 
the conformational state of a dendrimer. Dendrimers of all 
generations generally exhibit a larger extent of back-
folding with decreasing solvent quality, i.e. decreasing 
solvation. However, being more flexible, the low 
generation dendrimers show the highest tendency towards 
back-folding as a result of poor solvation compared to the 
higher generation dendrimers. NMR studies performed on 
PPI dendrimers concluded that a nonpolar solvent like 
benzene, poorly solvates the dendrimers favouring 
intramolecular interactions between the dendrimer 
segments and back-folding. But, a weakly acidic solvent 
like chloroform can act as a hydrogen donor for the interior 
amines in a basic dendrimer like PPI, leading to an 
extended conformation of the dendrimer because of 
extensive hydrogen bonding between the solvent and the 
dendrimer amines. Both experimental as well as theoretical 
studies on amino-terminated PPI and PAMAM dendrimers 
(polar dendrimers) show the tendency that nonpolar aprotic 
(poor) solvents induce higher molecular densities in the 
core region as a result of back-folding, whereas polar 
solvents solvate the dendrimer arms and induce a higher 
molecular density on the dendrimer surface. Backfolding of 
the polar surface groups may expose the more hydrophobic 
dendrimer parts to the surroundings leading to a decreased 
surface polarity of the back-folded dendrimer 
66
. 
3. Effect of Salt 
High ionic strength (high concentration of salts) has a 
strong effect on charged PPI dendrimers and favours a 
contracted conformation of dendrimers, with a high degree 
of back-folding somewhat similar to what is observed upon 
increasing pH or poor solvation. At low salt conditions, the 
repulsive forces between the charged dendrimer segments 
results in an extended conformation in order to minimize 
charge repulsion in the structure
85
. 
4. Effect of Concentration 
In dendrimers with flexible structures the conformation is 
not only affected by small molecules like solvents, salts or 
protons, but may also be sensitive to larger objects, such as 
other dendrimers or surfaces which can have a great affect 
on the molecular density and conformation of the 
dendrimer. Small angle X-ray scattering (SAXS) 
experiments performed on PPI dendrimers (G4, G5) in a 
polar solvent like methanol show that the molecular 
conformation of dendrimers upon increasing concentration 
becomes increasingly contracted. This molecular 
contraction may minimize the repulsive forces between the 
dendrimer molecules and increase the ability of the 
dendrimers to exhibit a more tight intermolecular packing. 
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SYNTHESIS OF DENDRIMERS: 
1. Convergent methodology 
This was pioneered by Hawker and Frechet in 1990’s. This 
strategy refers to the inward growth by gradually 
assembling surface units with reactive monomers. The 
deactive side products produced during reactions gets 
easily separated by purification, but this becomes harder in 
higher generations due to similarity in products and 
reactants. The convergent methodology suffers from one 
major limitation that it gives low yield in the synthesis of 
large structures and hence is suitable for production of only 
lower generation dendrimers.
19, 87
 
2. Divergent Method 
Divergent Method involves the coupling of monomeric 
molecules that possesses reactive and protective groups 
with the multifunctional core moiety which leads to 
stepwise addition of generations around the core followed 
by removal of protecting groups. PAMAM‑NH2 
dendrimers were firstly synthesized by coupling 
N‑(2‑aminoethyl) acryl amide monomers to an ammonia 
core and today they are the most systematically synthesized 
and commercialized family of dendrimers using this 
methodology. This method offers an advantage of 
producing modified dendrimers by changing the end groups 
and in turn their physicochemical properties can be altered 
as per the required application. Although, this approach 
suffers from limitation of structural defects due to 
incomplete reaction of groups which can be trounced by the 
excessive addition of monomeric units.
88,89
 
 
 
Figure 2: Synthesis approaches of dendrimers (A) Convergent method (B) Divergent method 
 
3. Double Exponential and Mixed Growth 
In this approach two products (monomers for both 
convergent and divergent growth) are reacted together to 
give an orthogonally protected trimer, which may be used 
to repeat the growth process again. Strength of double 
exponential growth is more subtle than the ability to build 
large dendrimers in relatively few steps.
87,90
 
4. Hypercores and Branched Monomers growth 
This method involved the pre-assembly of oligomeric 
species which can be linked together to give dendrimers in 
fewer steps or higher yields. 
 
MECHANISMSOF DRUG DELIVERY:  
Dendrimers are particularly attractive as they offer a high 
drug-loading capacity. Due to the well defined 3D structure 
and many surface functional groups, drug molecules can be 
loaded both in the interior of the dendrimers as well as 
attached to the surface groups. Dendrimers can function as 
drug carriers either by encapsulating drugs within the 
dendritic structure or by interacting with drugs at their 
terminal functional groups via electrostatic or covalent 
bonds forming prodrug. Encapsulation of drugs and 
dendrimer-drug conjugates
91-92 
  are two main methods of 
dendrimer drug delivery. 
1. Non-covalent Encapsulation of Drugs / Host –Guest 
Relation 
Incorporation of small organic molecules may be a result of 
non‑bonding interactions with specific groups within 
dendrimer, i.e. just physical entrapment 
Encapsulation of drugs uses the satiric bulk of the exterior 
of the dendrimer or Interactions between the dendrimer and 
drug to trap the drug inside the dendrimer. Such a system 
can be used to encapsulate drugs and provide controlled 
delivery. Initial studies of dendrimer as potential delivery 
systems focused on their use as unimolecular micelles and 
‘dendritic boxes’ for the noncovalent encapsulation of drug 
molecules. For example, in early studies, DNA was 
complexed with PAMAM dendrimers for gene delivery 
applications, and hydrophobic drugs and dye molecules 
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were incorporated into various dendrimer cores. An 
advantage of using dendritic unimolecular micelles rather 
than conventional polymeric micelles is that the micellar 
structure is maintained at all concentrations because the 
hydrophobic segments are covalently connected
93
.  
Dendrimers can be used as dendritic boxes and 
unimolecular micelles (dendrimer‑drug networks) for the 
incorporation of hydrophobic/hydrophilic molecules by 
host guest interactions inside their empty cavities 
(nanoscale containers) present around core.
94,95
 Jansen et al. 
were the first to entrap the rose bengal dye molecules in 
PPI dendrimers by using tert‑butyloxycarbonyl (t‑Boc) 
groups and led to the production of stable dendritic box that 
possess the bulky amino groups on the dendrimer surface.
96
 
The dendritic unimolecular micelles contain the 
hydrophobic cores surrounded by hydrophilic shells and 
they offer an advantage over conventional polymeric 
micelles such that the micellar structure is maintained at all 
the concentrations because the hydrophobic segments are 
covalently connected. 
2. Covalent Dendrimer–Drug Conjugates 
Alternatively, the exploitation of well‑defined multivalent 
aspect of dendrimers allows the attachment of drug 
molecules to its periphery that result in complex formation. 
The resultant complexes are formed either due to the 
electrostatic interactions between the drug and dendrimer 
or conjugation of the drug to dendrimer molecule. Through 
electrostatic interactions, various ionizable drugs form 
complexes with the large number of ionizable terminal 
surface groups of dendrimers.
97
 
In dendrimer–drug conjugates, the drug is attached through 
a covalent bond either directly or via a linker/spacer to the 
surface groups of a dendrimer. Dendrimers have been 
conjugated to various biologically active molecules such as 
drugs, antibodies, sugar moieties and lipids .The drug 
loading can be tuned by varying the generation number of 
the dendrimer, and release of the drug can be controlled by 
incorporating degradable linkages between the drug and 
dendrimer. 
Moreover, the drugs can be covalently conjugated to 
dendrimers through some spacers that may include PEG, 
p‑amino benzoic acid, p‑amino hippuric acid and lauryl 
chains etc., or biodegradable linkages such as amide or 
ester bonds. This prodrug approach has been found to 
increase the stability of drugs and has affected their release 
kinetics significantly. Several researchers have successfully 
conjugated naproxen,
98
 propranolol
92
 with PAMAM 
dendrimers. The results have shown the enhanced solubility 
and controlled release of drugs from these complexes in 
comparison to the pure drug. Apart from these, many 
anticancer drugs have also been conjugated and used for 
drug targeting. For example, epirubicin prodrug was 
developed by conjugating it with PEG dendrimers 
containing aminoadipic acid as branching molecules. These 
conjugates exhibited increased blood residence time and 
showed improved therapeutic action. The study revealed 
that PEG dendrimers increased the stability of bound drug 
toward chemical degradation and hence can be used 
potentially in the development of prodrugs of large 
molecules.
99
 
Conjugates of PAMAM dendrimers with cisplatin, a potent 
anticancer drug with non-specific toxicity and poor water 
solubility show increased solubility, decreased systemic 
toxicity and selective accumulation in solid tumors. 
Furthermore, the dendrimer–platinum complex has been 
found to show increased efficacy relative to cisplatin in the 
treatment of subcutaneous B16F10 melanoma. By using a 
careful synthetic strategy with two different chain end 
functionalities, it is also possible to attach both 
hydrophobic model drugs and PEO moieties to the 
dendrimer periphery in a controlled manner. Aliphatic 
polyester dendrimers based on 2,2-
bis(hyroxymethyl)propionic acid are promising dendrimer 
backbones for the development of anticancer drug 
conjugates
100
.  
 
Figure 3: Different types of drug‑dendrimer interactions. 
 
APPLICATION OF DENDRIMERS IN DRUG 
DELIVERY 
Over the past 30 years greater attention has been focused 
on development of controlled and sustained drug delivery 
systems. Amongst the extensive research has been carried 
in designing of polymeric drug delivery systems
101
. 
The development of dendrimer based efficient drug 
delivery systems has attracted a great deal of attention over 
the last few years. Unlike traditional polymers, dendrimers 
can be obtained in precise molecular weights even at high 
generations, which as previously highlighted can provide a 
reproducible pharmacokinetic behavior. This feature makes 
them ideal candidates for drug delivery applications. 
However, efficient drug delivery systems should meet other 
criteria, such as: (i) structural control over the size and 
shape of drug or imaging-agent cargo-space; (ii) 
biocompatibility, non-toxic polymer/pendant functionality; 
(iii) precise, nanoscale-container and/or scaffolding 
properties with high drug-loading capacity; (iv) well-
defined scaffolding and/or surface modifiable functionality 
for cell specific targeting moieties; (v) lack of 
immunogenicity; (vi) appropriate cellular adhesion and 
internalization, (vii) adequate bio-elimination or 
biodegradation; (viii) controlled or stimuli-responsive drug 
release features; (ix) molecular level isolation and 
protection of the drug against inactivation during transit to 
target cells; (x) minimal non-specific cellular and blood–
protein binding properties; (xi) ease of consistent, 
reproducible, clinical grade synthesis. 
1. Dendrimers in CNS Drug Delivery 
As the vast majority of potential CNS compounds have 
limited brain uptake, they may benefit from the use of 
advanced delivery systems in order to cross the BBB. The 
drug is encapsulated in, or associated to the particle, 
thereby masking its physiochemical characteristics
102.
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Nanomedicine has shown great potential for the treatment 
of many CNS diseases. Nanomedicine is the biomedical 
and pharmaceutical application of nanotechnology for 
making nanocarriers of therapeutics and imaging agents, 
nanoelectronic biosensors, and nanodevices with 
nanostructures. A number of nanocarrier delivery systems, 
including dendrimers, liposomes,  polymeric micelles,  
linear polymers, quantum dots, and iron oxide 
Nanoparticles have been developed and have demonstrated 
promising properties in CNS drug deliver
103
. Among these, 
much attention has been paid to dendrimers because of 
their advantages, which include (1) the ability to maintain 
drug levels in a therapeutically desirable range, (2) 
increased half-life, (3) increased solubility, stability, and 
permeability of drugs, (4) the capability to deliver a variety 
of drugs, (5) reduced macrophage uptake, (6) targeting 
ability, (7) facile passage across biological barriers by 
transcytosis, (8) rapid cellular entry, (9) improved delivery 
efficiency, and (10) reduced side effects by targeted 
delivery.
27, 104, 105
 
Polyesters based dendrimers have been proposed for CNS 
regenerative medicine. Dhanikula et al. 
106, 107
 suggested the 
use of polyether-copolyester (PEPE) dendrimers 
conjugated with d-glucosamine, and loaded with 
methotrexate (MTX) in order to allow a better delivery 
across the BBB. The results revealed that the efficacy of 
MTX-loaded dendrimers was established against U87 MG 
and U 343 MGa cells (two glioma cell lines). In vitro 
studies revealed that glucosylated dendrimers were 
internalized by endocytosis in significantly higher amounts 
than non-glucosylated dendrimers by both the cell lines. 
Moreover, the amount of MTX-transported across an in 
vitro model of the BBB was three to five times more after 
loading in the dendrimers, which indicates that 
glucosylation further increased the cumulative permeation 
of dendrimers across BBB, and hence increased the amount 
of MTX available across it. This work evaluated a different 
set of dendrimers, as well as different strategy, for potential 
use delivery across the BBB. However, it should be 
considered with caution, as only in vitro models were used, 
and the in vivo proof of concept is yet to be demonstrated. 
Prieto et al. 
108
 investigated the cytotoxicity of sulfadiazine 
complexed with fourth-generation PAMAM dendrimers. 
Cell culture studies using fibroblasts (Vero cells) and 
macrophages (J-774 cells) revealed that the dendrimeric 
sulfadiazine complexes did not affect membrane integrity 
at low concentrations (0.03!M). Moreover, cytotoxicity 
tests using human intestinal adenocarcinoma cell line 
(Caco-2 cells) showed that dendrimeric sulfadiazine did not 
reduce viability of Caco-2 cells over the tested 
concentrations as compared to that for PAMAM(G4). 
Remarkably, the in vivo study has shown that brain and 
muscle of Wistar rats are the main targets of intravenous 
administration of dendrimeric sulfadiazine, which can be 
advantageous for drug delivery applications directed to 
central nervous system. 
2. Dendrimers in Oral Drug Delivery 
Despite of tremendous innovations in drug delivery, the 
oral route remains the preferred route for administration of 
therapeutic agents because of accurate dosage, low cost 
therapy, self medication, non invasive method and ease of 
administration leading to high level of patient 
compliance.
109
 
Dendrimers are suitable candidate in oral drug delivery 
because dendrimers loosened the tight junctions of 
epithelial layer and thus an improvement in the absorption 
of small molecular weight drugs was achieved 
110
. The 
transepithelial transport and toxicity of polyamidoamine 
dendrimers as carriers for oral drug delivery has been 
reviewed by Sadekar and Ghandehari 
111
 
Kolhe et al. 
112
 demonstrated that ibuprofen predominantly 
forms a complex with PAMAM (G3 and G4) dendrimers 
because of the ionic interaction between the –NH2 end 
groups and the carboxyl group of ibuprofen. In this work, 
they demonstrated that the in vitro release of ibuprofen 
from drug–dendrimer complex is appreciably slower 
compared to pure ibuprofen. Moreover, the FITC-labeled 
dendrimer-complexed drug enters human lung epithelial 
carcinoma A549 cells much faster than pure drug, 
suggesting that dendrimers may be able to carry the 
complexed drug inside cells efficiently. 
In another work Kolhe et al 
21
 synthesized a fourth-
generation PAMAM (PAMAM-OH) dendrimer covalently 
linked to ibuprofen using dicyclohexylcarbodiimide (DCC) 
as a coupling agent. A high payload nanocarrier was 
obtained; 
113
 molecules of ibuprofen were covalently 
conjugated to one molecule of PAMAM-OH (G4) 
dendrimer. FITC-labeled dendrimer–drug conjugate 
nanoparticles internalization was evaluated in vitro once 
using A549 cells. The pharmacological activity of the 
dendrimer–ibuprofen conjugate was compared to pure 
ibuprofen at various time points by measuring the 
suppression of prostaglandin E2. Results demonstrated the 
high internalization efficiency of the FITC-labeled 
dendrimer–drug conjugate and superior therapeutic activity 
due to faster prostaglandin E2 suppression. Thus, the 
results suggest that the dendrimer–ibuprofen conjugate 
improve the drug efficacy by enhanced cellular delivery, 
and may produce a rapid pharmacological response. 
3. Dendrimers in Nasal Drug Delivery 
Transmucosal routes of drug delivery (i.e., the mucosal 
linings of the nasal, rectal, vagina, ocular and oral cavity) 
offer distinct advantages over peroral administration for 
systemic drug delivery. These advantages includes possible 
bypass of the first pass effect, avoidance of pre-systemic 
elimination of gastro intestinal tract and depending on the 
particular drug.
114 
Nasal administration offers an interesting 
alternative for achieving systemic drug effects to the 
parenteral route, which can be inconvenient or oral 
administration, which can result in unacceptably low 
bioavailabilities.
115 
Polyamidoamine (PAMAM) dendrimer has draws attention 
for nose-to-brain targeting. These dendrimers are repetitive 
branches that grow from a core. Many versatile molecules 
can be attached to their surface. Kim et al. connected an 
arginine onto the surface of a PAMAM dendrimer 
116
. This 
resulted in nanoparticles with a size of 188.7 ± 1.9 nm and 
a charge of +22.3 mV. Small interference RNA (siRNA) 
targeting against the high mobility group box 1 protein 
(HMGB1) was electrostatically attached onto the 
nanoparticles. HMGB1 is released by dying cells and acts 
as a danger signal, thereby aggravating the damage of a 
stroke or other neurotoxic insults. Upon intranasal 
administration, they observed a wide distribution of the 
construct into the brain, including the hypothalamus, the 
amygdala, the cerebral cortex, and the striatum. Moreover, 
the localization of the PAMAM dendrimer and the siRNA 
was associated with an efficient knock-down of the protein 
of interest: HMGB1. When a stroke was induced into 
animals, the group that received the intranasal 
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administration of the construct had a remarkably decreased 
infarction volume. 
The potential of mucoadhesive gel of dendrimers 
formulations for nose to brain delivery was also displayed 
by Perez et al. 
117
. They coupled radioactive siRNA to 
PAMAM dendrimers to form dendriplexes, and formulated 
these particles into mucoadhesive gels containing either 1% 
(w/w) chitosan or 0.25% (w/w) carbopol 974P NFTM. 
These gels were prepared by blending the chitosan or 
carbopol with 23% (w/w) of thermosensible poloxamer to 
obtain in-situ gelation. Such a thermosetting gel has a 
phase transition below the temperature in the nasal cavity 
(32 °C to 35 °C) and above room temperature. Therefore it 
can be administered as a liquid. Different concentrations of 
the different gels were tested and no toxicity was observed. 
Two intranasal doses were necessary to achieve higher 
brain concentrations of radioactivity than achieved by 
intravenous administration of dendriplexes or intranasal 
administration of naked siRNA. 
4. Dendrimers in Gene Delivery 
The ability to transfer genetic material efficiently, into the 
nucleus and cytoplasm of eukaryotic cells may allow 
treatment of a variety of genetic disorders. There are so 
many vectors and physical methods are reported for in vivo 
Gene delivery. 
Commonly two approaches viz. viral and non‑viral based 
are being used to facilitate the gene delivery to target cells. 
Although viral carriers (Synthetic DNA delivery systems) 
can achieve rapid transfection, but low efficiency, 
immunological and oncologic adverse effects associated 
with these vectors has remained a topic of concern
118-120
.  
Non‑viral gene delivery vectors offer the usage of 
natural/synthetic molecules or physical forces to transfer 
genetic material to targeted cells. Several advantages such 
as ease of fabrication, targeting ability, potential for repeat 
administration and low immune response have led to the 
usage of non‑viral vectors preferably for gene therapy. 
Dendrimers are one of the most useful non-viral gene 
delivery systems and play a significant role in the 
development of non-viral vectors for gene delivery due to 
their ability to transfect cells without inducing toxicity, the 
high charge density and tunable surface functional groups, 
thus allowing optimal condensation and formation of 
nanostructures with DNA, the so-called “dendriplexes”. 
Many factors affect the efficiency of non-viral gene 
delivery systems. For successful gene therapy the genetic 
material should be permanently integrated and expressed 
by cells. In this context, Galetti et al.
121
 demonstrated that 
antisense oligonucleotides (ONs, gene-specific sequences 
of nucleic acids with 15–25 bases) directed to LMP1 
mRNA, effectively suppressed LMP1 gene expression, 
which plays a key role for growth transformation and 
immortalization of B lymphocytes. The efficiency of three 
cationic carriers on the delivery of anti-LMP1-ON to their 
site of action in Epstein Barr virus (EBV)-infected B 
lymphocytes was investigated. Results showed that 
liposomes, dendrimers or transferrin-PLL-conjugated ON 
were internalized by the cells at an extent several fold 
higher than that of the naked oligomers. Using Superfect®, 
a dendrimeric polycation with terminal amine groups, a 
higher intracellular concentration of ON was obtained as 
observed by both cytofluorimetric and confocal microscopy 
analyses. However, there was some evidence of toxicity 
induced by the positively charged dendrimers on the 
lymphocytes’ membranes, and the lack of intracellular 
mRNA-ON duplex formation and of LMP1 mRNA 
degradation indicated a failure of this carrier. 
Among various commercially available dendrimers, 
PAMAM dendrimers have received the most attention as 
potential non‑viral gene delivery agents due to their 
cationic nature which enables deoxyribonucleic acid 
(DNA) binding at physiological pH.
122
 
Pandita et al. prepared dendrimer based gene delivery 
vectors taking advantage of the cationic nature and the 
“proton‑sponge” effect of these dendrimers. 
Arginine‑glycine‑aspartic (RGD) nanoclusters were 
formed by conjugation of G5 and G6 PAMAM dendrimers 
with a varying number of peptides containing the RGD 
motif, in view of its targeting capabilities. Authors reported 
that the system wherein G6 PAMAM dendrimer was 
conjugated to eight peptide arms enhanced the gene 
expression in mesenchymal stem cells and presented a 
2‑fold higher bone morphogenetic protein‑2 expression in 
comparison to the G6 native dendrimer.
123
 Various 
published literature suggests that functionalized dendrimers 
are much less toxic than the native dendrimers. Same group 
synthesized a new family of gene delivery vectors 
consisting of G5 PAMAM dendrimer core randomly linked 
to hydrophobic chains (with varying chain length and 
numbers). In vitro studies revealed a remarkable capacity 
of these vectors for internalizing pDNA with very low 
levels of cytotoxicity, being this effect positively correlated 
with the CH2 content present in the hydrophobic moiety. 
The results demonstrated that vectors containing the 
smallest hydrophobic chains showed the higher gene 
expression efficiency.
124
 Further, functionalized PAMAM 
dendrimers exhibited low cytotoxicity and 
receptor‑mediated gene delivery into mesenchymal stem 
cells and transfection efficiencies superior to those 
presented by native dendrimers and by partially degraded 
dendrimers.
125
 
The protection of DNA from in vivo degradation by the 
vectors is another key feature for success in gene delivery. 
Diaz-Mochon et al. 
126
 showed that a hybrid combination of 
PAMAM and peptide dendrimers, the so-called peptoid 
dendrimers, were able to transfect cells with higher 
efficiency than the PAMAM counterpart, and were 
nontoxic. In part, this work supported previous findings 
which demonstrated that combination of primary and 
secondary amines generates a “proton sponge” effect, 
which can facilitate theDNAtransfection process, by 
promoting the release of the plasmid from the cytoplasmic 
lysosome. Thus, efficiency of dendrimer/DNA complexes 
may be favored by prolonging the release of plasmid. 
As aforementioned, cationic PAMAM dendrimers have 
proved to efficiently mediate transfection of DNA into a 
variety of mammalian cells, in vitro. However, as 
highlighted, the major drawback of high-generation 
cationic dendrimers is their associated cytotoxicity. 
Anionic dendrimers, on the other hand, have shown no 
cytotoxic effect on cells over a broad range of 
concentrations. Hussain et al.
127
 have reported the 
successful use of ONs conjugated with pentaerythritol-
based anionic dendrimers in inhibiting cancer-cell growth. 
In vitro studies using cancer cells showed that ONs-
dendrimer conjugates enhance the cellular uptake, up to 
four times as compared to that for naked ONs. These data 
clearly demonstrated that anionic ONs-dendrimer 
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conjugates may represent attractive alternatives to cationic 
non-viral vectors for the delivery of gene silencing ONs. 
However, it is not known whether the system may facilitate 
the delivery of duplex siRNA for gene silencing by RNA 
interference. 
Vincent et al.
128
 investigated the efficacy in cancer therapy 
of non-viral gene transfer using the anti-angiogenic 
angiostatin (Kringle 1–3) and tissue inhibitors of 
metalloproteinases (TIMP) genes. This study revealed that 
it was possible to inhibit tumor growth and angiogenesis by 
using PAMAM dendrimers-like superfectant associated 
with 36-mer anionic oligomers (ON36) for delivering 
angiostatin and (TIMP)-2 genes. 
Luo et al.
129
 revealed the low cytotoxicity of PEG-modified 
PAMAM and their efficiency on the DNA delivery. These 
systems were obtained using low generation dendrimers 
with PEG chains, which mimics the fractured high-
generation dendrimers. In fact, the proposed molecules 
showed a 20-fold increase in transfection efficiency as 
compared to that of partially degraded dendrimer controls. 
5. Dendrimers in Cancer Treatment 
Dendrimers are attractive vehicles for delivery of 
antineoplastic agents at their target site. The flexible 
branches of a dendrimer, when constructed appropriately, 
can provide a tailored sanctuary containing voids that 
provide a refuge from the outside environment wherein 
drug molecules can be physically trapped 
130
. Encapsulation 
of hydrophilic, hydrophobic, or even amphiphilic 
compounds as guest molecules within a dendrimer 
131
 can 
be enhanced by providing various degrees of multiple 
hydrogen bonding sites or ionic interactions 
130 
or highly 
hydrophobic interior void spaces 
132
. 
Covalent linkage of small molecule drug candidates to a 
dendrimer enhances the pharmacological properties of the 
drug. In cancer chemotherapy, these desirable size-based 
features are reinforced by the enhanced permeability and 
retention (EPR) effect that improves the delivery of 
macromolecules to tumors. 
Folate has been studied as dendrimer-based drug targeting 
to the cancer cells. Folate is an attractive small molecule 
for use as a tumor targeting ligand because the membrane-
bound folate receptor (FR) is over expressed on a wide 
range of human cancers, including those originating in 
ovary, lung, breast, endometrium, kidney and brain 
133
. As 
a small molecule, it is presumed to be non-immunogenic, it 
has good solubility, binds to its receptor with high affinity 
when conjugated to a wide array of conjugates, including 
protein toxins, radioactive imaging agents, MRI contrast 
agents, liposomes, gene transfer vectors, antisense 
oligonucleotides, Ribozymes and antibodies 
133, 134
 . Upon 
binding to the folate receptor, folate-conjugated drug 
conjugates are shuttled into the cell via an endocytic 
mechanism, resulting in major enhancements in cancer cell 
specificity and selectivity over their non-targeted 
formulation counterparts 
133, 134
. Monoclonal antibodies are 
also used in dendrimer-based targeting because they 
recognize and selectively bind to tumor associated antigens 
(TAAs) 
135
. 
Transferrin is a β-globulin (β1-glycoprotein) and facilitates 
the transport of ferric ion (Fe3+) through transferring 
receptors on the plasma membrane. In fact, the use of 
transferrin as a ligand has been explored as a suitable 
delivery system for site-specific delivery to tumors
136
. PLL 
covalently linked with transferrin for delivery of ONs when 
exposed to human leukemic (HL-60) cells have been stated 
to promote apoptosis to a greater extent as compared to free 
ONs. 
Another good example of PAMAM dendrimer-based multi-
functional devices (target the desire cells, releasing the 
desired drug and monitoring their internalization 
fluorescent probe) has been reported by Islam et al.
 137
. This 
group partially acetylated PAMAM dendrimers (G5) that 
were then conjugated with FITC, FA and MTX. These 
were devised to target tumor cells through the folate 
receptor, while releasing an anti-tumor drug intracellularly. 
They showed that HPLC analysis is a valuable technique to 
determine the purity and stability of dendrimer-based 
complexes 
Yang et al.
 138
 synthesized FITC- and biotin-linked 
PAMAM dendrimer (G5) conjugates and investigated their 
ability for targeting cancer cells. The bifunctional 
conjugate (FITC–biotin–dendrimer) exhibited much higher 
internalization by HeLa cells than the conjugate without 
biotin. The uptake was found to be energy- and dose-
dependent, and could be effectively blocked by dendrimer-
conjugated biotin. The results indicate that the 
biocompatible biotindendrimer conjugate can be a 
promising nano-platform for therapy and diagnosis of 
tumors. 
An alternative approach to the development of dendrimers 
as anticancer drug carriers is to exploit their well-defined 
multivalency for covalent attachment of drug molecules to 
the dendrimer periphery. The drug loading can be tuned by 
varying the generation number of the dendrimer, and 
release of the drug can be controlled by incorporating 
degradable linkages between the drug and dendrimer. For 
example, encapsulation of the well-known anticancer drug 
cisplatin within PAMAM dendrimers gave conjugates that 
exhibited slower release, higher accumulation in solid 
tumors, and lower toxicity compared to free cisplatin
139
. In 
this regard, Malik et al.
 140
 prepared anticancer prodrugs, 
complexed carboxylate-terminated PAMAM dendrimers 
with cisplatin. They observed that cisplatin molecules can 
be released from the dendrimer scaffold by hydrolysis. 
Moreover, the prodrugs showed sustained release behavior 
(<1% after 80 h), much greater maximum tolerated dose, 
bioavailability of cisplatin, and prolonged survival period 
of tumor-bearing mice. Similarly, Malik and Duncan 
141
 
showed that the dendritic polymer palatinates may be 
administered intravenously, orally, parentally, 
subcutaneously, or topically to an animal with a malignant 
tumor in an amount which effectively inhibits the growth of 
the tumor. Also, dendritic polymer platinates exhibit high 
drug efficiency, high drug carrying capacity, good water 
solubility, good stability on storage, reduced toxicity, and 
improved antitumor activity in vivo. On the other hand, the 
work of Balogh et al. 
142
 showed the encapsulation of silver 
salts within PAMAM dendrimers produced conjugates that 
exhibited slow silver release rates and antimicrobial 
activity against Staphylococcus aureus, Pseudomonas 
aeruginosa, and Escherichia coli bacteria. 
Tuo Wei et al disclosed an original supramolecular 
nanomicellar system based on the amphiphilic dendrimer 
AmDM, which is able to effectively deliver the clinical 
anticancer drug DOX, enhance anticancer activity, and 
combat drug resistance while obviating systemic toxicity. 
This AmDM/DOX nanomicelle features several favorable 
advantages as therapeutic options in cancer therapy, 
including (i) high drug loading. This property is primarily 
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ascribable to the unique dendritic structure which, upon 
self-assembly, results in micelles with large, low-density 
hydrophobic core able to accommodate substantial amount 
of drugs; (ii) small micellar size (10 nm) with narrow size 
distribution; such small-sized nanoparticles favor deeper 
penetration into inner tumor regions and concurrently 
prolong overall circulation time for beneficial accumulation 
in tumor tissue via EPR effect; (iii) rapid and effective 
cellular uptake mainly via boosted macropinocytosis; (iv) 
enhanced drug release at acidic pH, leading to 
advantageously promoted drug release at tumor lesions, 
normally more acidic than healthy tissues; and (v) effective 
inhibition of drug efflux. Based on these multiple 
advantages, AmDM/DOX micelles can effectively enhance 
DOX therapeutic efficacy and combat drug resistance. 
Concomitantly, AmDM/DOX nanomicelles can drastically 
reduce the systemic toxicity of doxorubicin in vivo through 
preferential delivery at tumor site via combined EPR effect 
and acid-promoted drug release. Given these encouraging 
results, this drug delivery system based on amphiphilic 
dendrimer AmDM constitutes a concrete promise as a 
therapeutic entity in cancer treatment
143
. 
Cancer Targeting imaging and therapy 
Choi and coworkers 
144
 have come up with an innovative 
mix-and-match scheme that promises to offset this gloomy 
prediction. These researchers have recently reported a 
cancer-targeting strategy that is reminiscent of the antibody 
toxin/immunoconjugate strategy where distinct, but linked, 
entities are used to first recognize and bind and then 
subsequently modify a cancer cell. Their strategy, however, 
has great potential to improve on both the ‘‘targeting’’ and 
‘‘payload’’ aspects of cancer therapy by, at first seemingly 
paradoxically, completely dividing these functions into 
separate dendritic clusters (Figure 4). The key to this 
approach was to include a DNA ‘‘zipper’’ on each 
dendrimer that allows the targeting cluster, composed of 
folate-derivatized PAMAM in proof-of-concept 
experiments 
145
, to be readily combined with the imaging or 
drug-carrying dendrimer by way of the complementary 
DNA strand 
144
. It can be envisioned that the production of 
libraries of dendrimers targeted to different cancer-specific 
biomarkers can be produced by a ‘‘mix-and matched’’ 
strategy by combining ‘‘off-the-shelf ’’ targeting and drug 
clusters as needed 
146
. Development of easily-customizable 
nanomedicine platforms that exploit the facile duplex DNA 
formation for the generation of hybrid nano clusters, thus 
circumventing the tedious synthesis of multiply-
functionalized dendrimers, offers hope that the next ten 
years will witness rapid expansion of dendrimer 
technologies that build on the painstaking advances of the 
past decade. 
 
Figure 4: DNA–dendrimer conjugates as potential cancer 
targeting imaging agents or therapeutics. (Adapted from 
Ref.
147
) Differentially functionalized dendrimers covalently 
conjugated to complementary deoxyoligonucleotides can 
readily form duplex combinatorial nanoclusters that 
possess cancer cell-specific ligands hybridized to an 
imaging agent or drug. Cell-specific targeting ligands (e.g., 
folic acid in one study) are appended to Dendrimer A, and 
Dendrimer B is conjugated with an imaging agent or drug. 
6. Dendrimers in Vaccines Delivery 
Most low molecular weight substances are not 
immunogenic; consequently, when it is desired to raise 
antibodies against small molecules, they must be 
conjugated to a macromolecule. In the past, natural proteins 
have commonly been used as carriers to generate 
antibodies to small molecules; now an alternative strategy 
using dendrimers has been demonstrated. In particular, 
unmodified PAMAM dendrimers that fail to elicit an 
antibody response on their own become haptenized upon 
protein conjugation and generate a dendrimer-dependent 
antigenic response 
148,149
.  
Dendrimers have optimal characteristics to fill the need for 
efficient immunostimulating compounds (adjuvants) that 
can increase the efficiency of vaccines. Also dendrimers 
can provide molecularly defined multivalent scaffolds to 
produce highly defined conjugates with small molecule 
immunostimulators and/or antigens 
150
. These molecules 
are ideal carriers of small antigens, making it possible to 
prepare multimeric antigenic conjugates with well-defined 
molecular properties for human uses and they do not induce 
adverse host responses, including immune and/or 
inflammatory reactions upon administration. The interest 
has focused on one specific class of dendrimers, namely, 
the peptide dendrons described in 2005 by Crespo et al. 
151
.  
The basic structure described by Tam 
152
 is a dendron 
constructed solely from lysine, taking advantage of the two 
amino groups (R and  ) that are present in each lysine 
molecule and act as branching points for logarithmic 
growth. A two-layer dendron thus has four free amino 
groups and a three-layer dendron has eight, equally divided 
between Rand  -amino groups. Tam coined the name 
“major antigenic peptide” (MAP) for such a structure 
derived from molecules of interest, not only limited to 
peptides, but also any small molecule that could bind 
covalently to the terminal amino groups of the MAP “core” 
dendron. 
7. Dendrimers as Ophthalmic vehicles 
The majorities of topically applied ocular drug-delivery 
systems are formulated either as solutions, ointments, or 
suspensions and suffer from various disadvantages such as 
quick elimination from the precorneal region, poor 
bioavailability, or failure to deliver the drug in a sustained 
fashion. Several research advances have been made in 
ocular drug delivery systems by using specialized delivery 
systems such as polymers, liposomes, or dendrimers to 
overcome some of these disadvantages. Ideal ocular drug-
delivery systems should be nonirritating, sterile, isotonic, 
biocompatible, and biodegradable. The viscosity of the 
final product should be optimized so that the dosage form 
does not run out of the eye. Dendrimers provide solutions 
to some complex delivery problems for ocular drug 
delivery. 
Some recent research efforts in dendrimers for ocular drug 
delivery include PAMAM dendrimers that were studied by 
Vandamme and Brobeck as ophthalmic vehicles for 
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controlled delivery of pilocarpine and tropicamide to the 
eye 
153
.  
PAMAM dendrimers with carboxylic or hydroxyl surface 
groups, have been reported in improving residence time 
and enhancing bioavailability of pilocarpine in the eye.
 154
 
In the New Zealand albino rabbit model, the residence time 
of pilocarpine in the eye was increased by using dendrimers 
with carboxylic or hydroxyl surface groups. These surface-
modified dendrimers were predicted to enhance pilocarpine 
bioavailability. 
In another study, dendrimer end groups were conjugated 
with aminosaccharides and sulfated aminosaccharides to 
obtain anionic dendrimers with unique biological properties 
155
. These glucosamine and glucosamine 6-sulfate 
dendrimers were studied in a rabbit model of scar tissue 
formation after glaucoma filtration surgery. These unique 
polymeric macromolecules increased the long-term success 
of the surgery from 30% to 80% when used together. 
In another study, lipophilic amino-acid dendrimers were 
used to study the long-term effect of use of dendrimer for 
delivery of an antivascular endothelial growth factor 
(VEGF) oligonucleotide (ODN-1) to the eye of rats with 
the aim of inhibiting laser-induced choroidal 
neovascularization (CNV). It was shown that dendrimer 
containing ODN-1 showed significantly greater inhibition 
of CNV over a 4–6 month period compared with ODN-1 
alone 
156
. Immunohistochemistry of the eye tissue after 
long-term treatment with dendrimers was conducted to 
determine if an immune response was generated after use 
of the dendrimer as a drug conjugate for treating eye 
diseases. It was determined that there was no significant 
increase in inflammatory response, proving that dendrimers 
could be used as a viable option for delivery of 
oligonucleotide to the eye for treating angiogenic eye 
diseases without concern of generating unwanted biological 
response. 
8. Dendrimers in Topical and Transdermal delivery 
Dendrimers have found recent applications in novel topical 
and transdermal delivery systems, providing benefits such 
as improved drug solubilization, controlled release, and 
drug-polymer conjugates (pro-drugs). The viscosity-
generation-number property of a dendrimer solution allows 
for ease of handling of highly concentrated dendrimer 
formulations for these applications. Dendrimers have been 
shown to be useful as transdermal and topical drug delivery 
systems for nonsteroidal anti-inflammatory drugs 
(NSAIDs), antiviral, antimicrobial, anticancer, or 
antihypertensive drugs. PAMAM dendrimers have been 
studied as carrier transdermal systems for the model 
NSAIDs: ketoprofen and diflunisal 
157
. It was found that the 
PAMAM dendrimer-drug formulations showed increased 
transdermal drug delivery compared with formulations 
lacking dendrimers. In vivo studies in mice showed 
prolonged pharmacodynamic responses and 2.73-fold 
higher bioavailability over 24 h for certain dendrimer-
containing drug solutions. 
In another study, transport of indomethacin through intact 
skin was enhanced in vitro and in vivo 
158
. The 
bioavailability of indomethacin was increased by using G4-
PAMAM dendrimers with terminal amino groups. There 
have also been studies where dendrimers failed to show 
enhancement in drug transport through intact skin. It is well 
known that the molecular diffusion through intact skin is 
related to the molecular weight of the permeant molecule. 
Because of their high molecular weights, dendrimers 
generally have low diffusion coefficients. Diffusion 
through skin is more favorable for molecules that have 
solubility in lipids as well as in water. It could be possible 
to synthesize dendrimers with appropriate physical-
chemical properties to facilitate drug transport through 
intact skin. Dendrimers with such favorable 
physicochemical properties could enhance transdermal 
transport of drugs by this mechanism. More research is 
warranted in this area to understand the structural-activity 
relationship of dendrimers in relation to skin transport. 
In contrast to transdermal delivery, the use of dendrimers 
for topical delivery to the skin has shown to be more 
promising. Two different kinds of dendrimers were shown 
to have antiviral activity in vitro when the dendrimers were 
added to the cells before being challenged with the viruses. 
The dendrimers studied were either PAMAM or polylysine 
dendrimers. In contrast, dendrimers added to the cells after 
they were challenged with the virus showed no antiviral 
activity. The study was carried out in an in vitro assay to 
determine dendrimer activity against herpes simplex virus 
(HSV) types 1 and 2. When tested in human foreskin 
fibroblast cells, both PAMAM and polylysine dendrimers 
showed activity against the virus. This study suggested that 
dendrimers could potentially be used as topical 
microbicides to be applied to the vaginal or rectal mucosa 
to protect against sexually transmitted diseases such as HIV 
or genital herpes. When tested against genital HSV 
infection in mice, two of the compounds showed significant 
reduction in infection rates when applied prior to 
intravaginal challenge. 
Dendrimers are able to improve drug properties such as 
solubility and plasma circulation time via transdermal 
formulations and to deliver drugs efficiently due to its 
highly water soluble and biocompatible nature. For 
example improving the drug permeation through the skin 
when PAMAM dendrimer complex with NSAIDs like 
Ketoprofen, Diflunisal and enhanced bioavailability of 
PAMAM dendrimers by using indomethacin as the model 
drug in transdermal drug application
157,158
. 
9. Dendrimers in Pulmonary drug delivery 
Polyamidoamine dendrimers with positive charge have 
shown the enhanced bioavailability in pulmonary delivery 
of low-molecular weight heparin (a negatively charged 
oligosaccharide) to treat vascular thromboembolism. In this 
formulation, dendrimer-drug complex was formed 
159
. 
Further studies showed that heparin encapsulated in 
pegylated dendrimers has a longer circulating half-time and 
increased pulmonary absorption 
160
. 
Pegylated dendrimeric micelles prolong the half-life of low 
molecular weight heparin (LMWH), Enoxaparin and 
increase the drug’s pulmonary absorption, thereby 
efficacious in preventing deep vein thrombosis (DVT) in a 
rodent model. Shuhua Bai have prepared dendrimers of 
LMWH entrapped in PEG these produced a significant 
increase in pulmonary absorption and the relative 
bioavailability of the formulation was 60.6% compared to 
subcutaneous LMWH. The half-life of the PEG–dendrimer-
based formulation was 11.9 h, which is 2.4-fold greater 
than the half-life of LMWH in a saline control formulation. 
When the formulation was administered at 48-h intervals, 
the efficacy of LMWH encapsulated in pegylated 
dendrimers in reducing thrombus weight in a rodent model 
was very similar to that of subcutaneous LMWH 
administered at 24-h intervals 
161
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In addition to dendrimers, cationic liposomes were used as 
carriers for heparin and showed enhanced pulmonary 
absorption. These cationic liposomes were prepared by 
conventional methods, i.e. lipid dispersion, solvent 
evaporation and extrusion 
162
. 
10. Dendrimer as Solubility enhancer 
With the discovery of new drug molecules today low 
solubility is the main hurdle to be overcome
163
. 
Approximately 40% of newly developed drugs are rejected 
by the pharmaceutical industry and will never benefit a 
patient because of low water solubility. Given the growing 
impact and need for drug delivery, a thorough 
understanding of delivery technologies that enhance the 
bioavailability of drugs is important. The high level of 
control over the dendritic architecture (size, branching 
density, surface functionality) makes dendrimers ideal 
excipients for enhanced solubility of poorly water-soluble 
drugs. Many commercial small-molecule drugs with 
anticancer, anti-inflammatory and antimicrobial activity 
have been formulated successfully with dendrimers, such 
as poly (amidoamine) (PAMAM), poly(propylene imine) 
(PPI or DAB) and poly(etherhydroxylamine) (PEHAM). 
Some dendrimers themselves show pharmaceutical activity 
in these three areas, providing the opportunity for 
combination therapy in which the dendrimers serve as the 
drug carrier and simultaneously as an active part of the 
therapy. Dendrimers are unimolecular micellar nature, due 
to have hydrophilic exteriors and hydro-philic interiors and 
form covalent as well as non-covalent complexes with drug 
molecules and hydrophobes, and enhance its solubilisation 
behaviour
164
. 
11. Dendrimers in Cellular delivery  
PAMAM dendrimers with lauryl chains to reduce toxicity 
and enhance cellular uptake, for example Dendrimer 
ibuprofen complexes entered the cells rapidly compared 
with pure drug (1 hr versus>3 hr), suggesting that 
dendrimers can efficiently carry the complexes drug inside 
cells
165
. 
12. Dendrimers as Bio mimetic artificial proteins 
Dendrimers are often referred to as “artificial proteins” due 
to their dimensional length scaling, narrow size 
distribution, and other bio mimetic properties. For 
examples PAMAM family, they closely match the sizes 
and contours of many important proteins and bio 
assemblies like insulin (3 nm), cytochrome C (4 nm), and 
haemoglobin (5.5 nm) are approximately the same size and 
shape as ammonia-core PAMAM dendrimers generations 
3, 4 and 5, respectively. Generation 2 dendrimer matches 
the width (2.4 nm) of DNA duplexes (form stable 
complexes with histone clusters to condense and store 
DNAwithin the nucleosome of cells.) and generations 5 and 
6 PAMAM dendrimers have diameters approximately 
equivalent to the thickness of lipid bilayer membranes 
(~5.5 nm) of biological cells
166, 167
. 
13. Dendrimers as Nano-Drugs 
Dendrimers as Nano-Drugs, useful as antiviral drugs 
against the herpes simplex virus can potentially 
prevent/reduce transmission of HIV and other sexually 
transmitted diseases (STDs) when Poly(lysine) dendrimers 
modified with sulfonated naphthyl groups. Show potent 
antibacterial biocides against Gram positive and Gram 
negative bacteria when PPI dendrimers with tertiary alkyl 
ammonium groups attached to the surface and Chitosan– 
dendrimer hybrids have been found to be useful as 
antibacterial agents, carriers in drug delivery systems, and 
in other biomedical applications
168
. 
14. Dendrimers in Site Specific Drug Delivery 
Effective targeted drug delivery systems have been a dream 
for a long time, but it has been largely frustrated by the 
complex chemistry that is involved in the development of 
new systems
169
. The concept of targeted drug delivery is 
designed for attempting to concentrate the drug in the 
tissues of interest while reducing the relative concentration 
of the medication in the remaining tissues. As a result, drug 
is localised on the targeted site. Hence, surrounding tissues 
are not affected by the drug
170
. 
The targeted delivery of chemotherapeutics is essential to 
reduce the side effects significantly associated with 
conventional therapy, where healthy tissues such as liver, 
spleen, kidneys and bone marrow can accumulate the toxic 
levels of drug. The site specific delivery of the drug could 
be achieved by surface modification of dendrimers 
employing various targeting moieties such as folic acid 
(FA), peptides, monoclonal antibodies and sugar groups.
171
 
Several successful active and passive targeting attempts 
were accomplished by engineering the branching units and 
surface groups of dendrimers. Patri et al. conjugated FA to 
G5 PAMAM dendrimer for the targeted delivery of 
methotrexate and observed receptor mediated drug delivery 
that demonstrated high specificity for KB cells 
overexpressing folate receptors and showed slower drug 
release.[35] The authors further conjugated the PhiPhiLux 
G1 D2, an apoptotic sensor to FA attached PAMAM 
dendrimers which showed 5 fold enhanced fluorescence, 
attributed to successful delivery of drug with cell‑killing 
efficacy.
172
  
pH and temperature-activated polymers are known to be 
successful drug delivery systems. Photochemical 
internalization (PCI) can facilitate site-specific delivery, 
e.g., escape of the macromolecules from endocytic vesicles 
into the cytosol. Lai et al. 
173
 conjugated doxorubicin (Dox) 
to PAMAM dendrimers via pH-sensitive and insensitive 
linkers, acid-labile hydrazone linkages (PAMAMhyd- Dox) 
and amide (PAMAM-amide-Dox), respectively. 
They combined doxorubicin-dendrimers with different PCI 
strategies to evaluate the cytotoxic effects. Results showed 
that both PCI strategies promoted the PAMAM-amide-Dox 
cytosolic distribution, but significantly enhanced the 
cytotoxicity of free Dox on human gingival cancer (Ca9-
22) cells at higher concentrations. The authors failed to 
develop a multi-modality cancer treatment, but their data 
provided insights on possible research directions, namely 
the need to exploit spacers other than amide-linkage in 
drug-polymer complexes. 
Wiwattanapatapee et al. 
174
 investigated the use of 
dendrimers for colon-specific drug delivery applications. In 
their studies, 5-aminosalicylic acid (5-ASA) was bound to 
the water-soluble dendrimer using different spacers 
containing azo-bond (e.g., p-aminobenzoic acid, PABA and 
p-aminohippuric acid, PAH). PAH provide the polymer 
conjugates a higher loading capacity (3 times) for 5-ASA 
as compared to that of dendrimer conjugates with PABA as 
the spacer. In vitro studies of rats with cecal content were 
carried out to investigate drug release from dendrimer 
conjugates. The release of 5-ASA from both conjugates 
was significantly slower as compared to that of 
sulfasalazine (SA), a commercial prodrug. Moreover, the 
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conjugate with PAH linker showed significantly higher 
amount of initial drug release than the conjugate with the 
PABA linker. As a consequence, the amount of drug 
released from PAMAM-PAH-SA was significantly higher 
than that of PAMAM-PABA-SA conjugate. This study 
nicely illustrated the potential use of PAMAM dendrimer 
for colon-specific drug delivery, and the important role of 
the spacers for the optimization of drug release. 
CD derivatives bearing peptides may be useful as carriers 
for transporting drugs to biological targets containing 
specific peptide receptors. Thus, peptide biorecognizability 
together with the CD host–guest complexation properties 
makes such systems suitable templates for the application 
in site-specific drug delivery. Much effort has beenmadeto 
complex low generation dendrimers with other polymers. 
For example, Dodziuk et al. 
175
 reported attempts to 
complex a first-generation dendrimer having four branches 
with α, β or γ cyclodextrins, found to be unsuccessful in 
their subsequentNMRstudies. Muhanna et al. 
176
 reported a 
different strategy, with the synthesis of tetradecavalent 
amino acid and peptide dendrimers based on a β -CD core. 
These were found to have great potential for application in 
MAP concept as a means to increase the peptide–receptor 
binding, and hence improve the site specificity of the drug 
delivery system.  
 
DENDRIMERS IN DIAGNOSIS: 
1. Dendrimers as molecular probes  
Due to their distinct morphology and unique 
characteristics, use as molecular probes. For Example, the 
immobilization of sensor units on the surface of dendrimers 
is a very efficient way to generate an integrated molecular 
probe, because of their large surface area and high density 
of surface functionalities
177
. 
2. Dendrimers as X-ray contrast agents 
Dendrimers are currently under investigation as potential 
polymeric X-ray contrast agents. Potential dendritic X-ray 
contrast agents using various organo metallic complexes 
such as bismuth and tin are used to obtain a high resolution 
X-ray image, several diseases or organs, such as 
arteriosclerotic vasculature, tumors, infarcts, kidneys or 
efferent urinary etc
178, 179
. 
3. Dendrimers as MRI contrast agents  
Magnetic resonance imaging (MRI) is an important tool in 
modern medicine, providing high-quality three-dimensional 
images without the use of harmful ionizing radiation. The 
signal intensity in MRI stems mainly from the relaxation 
rate of in vivo water protons and is enhanced by the 
administration of a contrast agent prior to the scan. Such 
agents include a paramagnetic metal ion that decreases the 
relaxation times of nearby water protons. Different groups 
of contrast agents are established for clinical application: 
gadolinium chelates, superparamagnetic iron oxide 
particles, and hepatobiliary contrast agents. However, the 
gadolinium chelates constitute the largest group of MRI 
contrast agents and are considered to be safe. 
Introduction of target specific moieties to the dendritic 
MRI contrast agents, to improve the pharmacokinetic 
properties of dendrimer contrast agents, for example folate 
conjugated Gd (III)–DTPA PAMAM dendrimer, which 
increased the longitudinal relaxation rate of tumor cells 
expressing the high affinity folate receptor
180,181
. 
The crucial properties of MRI contrast agents include good 
biocompatibility, low toxicity, and high relaxivity. Low 
molecular weightMRI contrast agents diffuse rapidly from 
blood vessels into the interstitial space and are excreted 
fromthe body very rapidly 
94
. Paramagnetic metal chelates 
such as Gd(III)-N,N�,N��,N���-tetracarboxymethyl- 
1,4,7,10-tetraazacyclododecane (Gd(III)-DOTA), Gd(III)- 
diethylenetriamine pentaacetic acid (Gd(III)-DTPA), and 
their derivatives are used as contrast agents for magnetic 
resonance imaging (MRI), because these metal chelates 
increase the relaxation rate of surrounding water protons 
182
.  
However, the shortcomings of these low molecular weight 
contrast agents include short circulation times within the 
body and inefficient discrimination between diseased and 
normal tissues. Subsequently, macromolecular Gd(III) 
complexes have been developed by conjugating Gd(III) 
chelates to biomedical polymers, including poly(amino 
acids), polysaccharides, and proteins to improve image 
contrast enhancement. These macromolecular agents have 
demonstrated superior contrast enhancement for blood pool 
imaging and cancer imaging in animal models. 
Unfortunately, the clinical application of macromolecular 
agents in general is limited by their slow excretion rate 
which results in their accumulation within the body, that is, 
the liver. In addition, the long residence time of MRI 
agents enhances the risk of potential toxicity by Gd(III) 
ions released during the metabolism of these agents 
183
, 
184
. 
On the other hand, Wiener et al. 
185
 developed a new class 
ofmagnetic resonance imaging contrast agents,Gd(III)- 
DTPA-based PAMAM dendrimers, with large proton 
relaxation enhancements and high molecular relaxivities. 
These 6th generation PAMAM dendrimers possess 192 
reactive terminal amines,which can be conjugated to the 
chelating ligand 2-(4-isothiocyanato-benzyl)-6-methyl-
(DTPA) through a thiourea linkage. This dendrimer has a 
relaxivity a six times higher than that of free Gd(III)-DTPA 
complex. In vivo experiments on rabbits show excellent 
MRI images of blood vessels and long blood circulation 
times (>100min) upon intravenous injection. In 
addition,Kobayashi et al. 
186
 synthesized small dendrimer-
based MRI contrast agents and investigated the relationship 
between relaxivity and dendrimer generations using 
Gd(III)-DTPA based PAMAM dendrimers. The results of 
this study revealed that relaxivities increased as the 
dendrimer generation increased, but there was no 
significant increase in relaxivities beyond 7th generation. 
4. Dendrimers for CNS Imaging and Diagnosis  
Imaging of CNS is an important tool for studying and 
monitoring the structure and functional changes in the brain 
and spinal cord. Advanced imaging can lead to a better 
understanding of the effect of cellular damage on CNS 
function and can help to improve the precision of 
neurological procedures.
187,188
 To date, surgical resection 
remains the main treatment for brain tumors. The success 
of brain tumor removal during surgery is highly dependent 
on the surgeon’s ability to differentiate tumor from normal 
tissues using subjective criteria that are not easily 
quantifiable. A recent interesting report revealed that Cy5- 
labeled free activatable cell-penetrating peptides (ACPPs) 
conjugated to PAMAM dendrimers delineated the margin 
between tumor and adjacent tissue and thereby improved 
the precision of tumor resection in mouse xenograft 
models.
189,190
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Contrast enhanced magnetic resonance imaging (MRI) is 
widely used for defining brain tumors in the clinic, but its 
ability to be used in tumor visualization is limited by the 
transient circulation life time, nonspecificity, and poor 
BBB permeability of the commercially available MRI 
contrast agents. Because the brain is the most complex 
organ in human body, the precision of brain tumor 
resection becomes more crucial and relevant than ever. It is 
of interest and the utmost urgency to investigate further 
dendrimer application in brain tumor imaging. In addition, 
the complete excision of a malignant brain tumor is also 
challenged by its infiltrative nature. Interest in 
nanoparticles has grown for the development of new 
imaging and diagnostic agents for the assessment of brain 
function and diagnosis of CNS disorders and diseases using 
structural imaging techniques, such as MRI, computed 
tomography (CT), positron emission tomography (PET), 
magnetoencephalography (MEG), and optical imaging.
188
 
Nanoparticles have been developed that have better body-
compartment distribution and tissue targeting than standard 
contrast agents.
191
  
Theoretically, nanoparticles used in drug delivery can be 
applied to deliver imaging agents and diagnostic molecules. 
Consequently, increasing attention has been paid to the 
development of nanoparticles that can fulfill multiple 
functions including therapy, imaging, and diagnosis. In 
addition to the extensive studies of dendrimers in drug 
delivery, the development of dendrimer-mediated CNS 
imaging and diagnosis has attracted considerable 
attention.
192,193
  
PAMAM-PEG-T7 was explored to deliver MRI contrast 
agents to liver and early brain glioma tumors.
194
 PAMAM-
PEG-T7 was conjugated with diethylene triamine 
pentaacetic acid (DTPA) and further chelated gadolinium 
(Gd) to yield Gd-DTPA-PAMAM-PEG-T7. The MRI 
results showed that Gd- DTPA-PAMAM-PEG-T7 could 
selectively identify liver cancer but not early glioma, 
suggesting that this nanoscaled MRI contrast agent might 
allow for selective and efficient diagnosis of tumors 
without the natural barrier.
194
 To overcome this natural 
barrier, a two-component targeted nanoprobe was 
developed on the basis of PAMAM dendrimer (G5) labeled 
with MR/optical imaging reporters and tumor 
vasculaturetargeted cyclic (RGDyK) peptides and 
angiopep-2 peptides.
195
 
It has been reported that brain tumor cells highly express 
both αVβ3 integrin and LRP receptor.
196,197
 This nanoprobe 
first targets the αVβ3 integrin expressed in the tumor 
vasculature. Second, the increased local concentration of 
the nanoprobe facilitates the association between angiopep-
2 peptides and LRP receptors on the vascular endothelial 
cells and further accelerates the BBB transversing of the 
nanoprobe via LRP receptor-mediated endocytosis. In vivo 
imaging studies illustrated that this nanoprobe could 
efficiently cross the intact 
BBB in normal mice and precisely delineate the boundary 
of the orthotopic U87MG human glioblastoma xenograft 
with a high target-to-background signal ratio.
195
 Another 
macromolecular MRI contrast agent was developed on the 
basis of dendrigraft poly-L-lysines (DGLs) modified with 
chlorotoxin (CTX) and a tumor-specific ligand and loaded 
with Gd-DTPA as a contrast agent. The MRI results 
showed that both signal intensity and duration were 
significantly enhanced in tumorbearing nude mice treated 
with CTX-modified contrast agent compared to those 
treated with an unmodified counterpart and a commercial 
control. Ion imaging is another powerful methodology to 
assess fundamental biological processes in live cells. 
However, this approach is limited by the efficiency of some 
ion-sensing probes and the fast leakage from cells. A 
dendrimer-based nanoparticle was developed to achieve 
better intracellular retention of fluorescent probes and to 
perform prolonged fluorescence imaging of intracellular 
ion dynamics.
198
  
A sodium dye, CoreNa Green, was encapsulated within a 
PEGylated PAMAM dendrimer (G5) to generate a sodium-
sensitive nanoprobe. This nanoprobe is very stable and 
possesses high sodium sensitivity and selectivity. This 
nanoprobe homogenously filled the entire cell volume and 
remained for a long duration without detectable alterations 
of functional cellular properties when it was loaded in 
neurons in live brain tissue. The same principle can be 
applied to other existing fluorescent dyes, generating new 
applications for live fluorescent imaging.
 198
 
In addition to their straight forward assembly, dendrimer 
based nanoprobes are promising for the noninvasive 
visualization of brain tumors with uncompromised BBB, 
providing the possibility for real-time optical-image-guided 
brain tumor resection during surgery. Thus, dendrimer-
based nanoprobes could become an attractive tool for CNS 
imaging and diagnosis.  
 
THERAPEUTIC APPLICATION OF DENDRIMERS 
1. Dendrimers in photodynamic therapy (PDT) 
In PDT Cancer treatment involves the administration of a 
light activated photosensitizing drug that selectively 
concentrates in diseased tissue. PDT has been shown to 
reduce tumors by direct cell killing, destruction of tumor 
neovasculature, and triggering of an acute inflammatory 
response that attracts leukocytes to the tumor 
199
. For 
example the photosensitizer 5-aminolevulinic acid has been 
attached to the surface of dendrimers and studied as an 
agent for PDT of tumorigenic keratinocytes. 
Dendrimers have been used as carriers for improved 
delivery of 5‑ aminolevulinic acid (a natural precursor of 
photosensitizer protoporphyrin 1X) that increases the 
accumulation of porphyrin in cells, which further results in 
toxicity.
200-200
 Recently, polymeric micelles encapsulating 
dendrimer phthalocyanine have been developed as a 
photosensitizer formulation for enhanced photodynamic 
effect.
203
 
More recently, G3 PAMAM grafted porous hollow silica 
nanoparticles (PHSNPs) were successfully fabricated as 
photosensitive drug carriers for PDT. The attachment of 
gluconic acid (GA) to this system was thereafter followed, 
for surface charge tuning. PAMAM‑ functionalized outer 
layer with a large number of amino groups provided high 
loading amount of aluminum phthalocyanine tetrasulfonate 
(AlPcS4), its retarded premature release and effective 
release to target tissue. The study demonstrated that 
irradiation of the AlPcS4 entrapped GA‑ G3‑ PHSNPs 
with light resulted in efficient generation of singlet oxygen 
that produced significant damage to tumor cells and 
suggested as effective photosensitizer formulation for PDT 
applications.
204
 
2. Dendrimers for boron neutron capture therapy 
(BNCT)  
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Boron therapy is concerned with the treatment of cancers 
that is based on Boron capture reaction
205
. The radiation 
energy generated from the capture reaction of low-energy 
thermal neutrons by 10B atoms has been used successfully 
for the selective destruction of tissue. Due to their well 
defined structure and multivalency, Dendrimers are a very 
fascinating compound for use as boron carriers
206
. 
The applicability of PAMAM dendrimers in investigating 
intratumoral delivery of agents for neutron capture therapy 
is remarkable in biomedical science. In a study by Wu et al. 
functionalized G5 PAMAM dendrimers and conjugated 
cetuximab specific to EGF receptor to starburst dendrimers 
that carried around 1100 boron atoms. The in vivo results 
revealed that accumulation of conjugates were 10 times 
higher in brain tumor tissues in comparison to healthy brain 
tissues. This study was first to demonstrate the efficacy of a 
boronated monoclonal antibody for boron neutron capture 
therapy of an intracerebral glioma.
207
 Dendrimer based 
boron neutron capture therapy in combination with EGF 
receptor targeting moieties can enhance the boron uptake in 
tumor tissues.
208
 
A similar strategy (e.g., cell targeted particles) was 
followed by Wu et al. 
209
, developed a vehicle for boron 
neutron capture therapy (BNTC). A heavily boronated 
PAMAM dendrimer was chemically linked to C225 by 
means of the heterobifunctional reagents N-succinimidyl 3-
(2-pyridyldithio)-propionate and N-(k-maleimido 
undecanoic acid)-hydrazide. Initial in vitro studies revealed 
that the F98EGFR glioma cells mentioned above 
specifically internalize the particles when compared to 
receptornegative F98 wild-type cells. Further in vivo 
studies were conducted by stereotactically implanting 
F98EGFR cells into the brains of Fischer rats. The targeted 
boronated dendrimers were administered 14 days after 
either convection enhanced delivery (CED) or direct 
intratumoral (i.t.) injection. Results revealed that not only 
were the targeted dendrimers receptor specific in vivo, but 
also that animals exposed to the tested therapy displayed 
higher survival rated when compared to controls. In this 
sense it appears that this strategy for using dendrimers as 
targeted particles for therapeutic usage is more favorable 
than the former. 
3. Gadolinium-based (Gd) neutron capture therapy 
(GdNCT) 
It is an alternative to BNCT that has been investigated due 
to Gd's high neutron absorbency properties, but has rarely 
been used as it is deemed too difficult to achieve 
therapeutic doses intravenously. Kobayashi et al. explored 
Gd-labeled PAMAM dendrimers for the delivery of MRI 
contrast agents that may also facilitate the use of neutron 
capture therapy to the sentinel lymph node, which is often 
imaged for breast cancer management
210,211
. Generation 2, 
4, 6, and 8 PAMAM dendrimers, ranging in sizes from 3 to 
12 nm, were evaluated to determine the optimal particle 
size for entering the lymphatic vessels while avoiding 
leaking, and it was shown that G6-PAMAM (9 nm) 
produced the earliest and most intense opacification of the 
sentinel lymph nodes with sufficient Gd concentrations for 
NCT. Conversely, G2- and G4 PAMAM do not retain in 
the lymphatic vessels, while G8-PAMAM is too large for 
rapid uptake. Based on these results, it was determined that 
gadolinium-labeled G6-PAMAM may simultaneous image 
and treat primary tumors or micro-metastasis in the sentinel 
lymph nodes. 
4. Dendrimeric-based artificial virus receptors 
Research on dendrimeric-based artificial virus receptors 
has attracted great deal of attention. Yamada et al.
 212
 
successfully synthesized a novel class of carbosilane 
dendrimer periphery-functionalized lacto-N-neotetraose, 
aimed to mimic dengue virus receptor. In another work 
213
, 
they synthesized carbosilane dendrimers 
peripheryfunctionalized with lactotriaose (GlcNAc#1-
3Gal#1-4Glc) with valencies of three, four, six, and 12 for 
use in a lectinbinding assay. The hexavalent 
glycodendrimer showed a 2500-fold larger binding effect 
than that of free lactotriaose, though the dodecavalent one 
exhibited only a 1200-fold larger binding effect. The same 
group also reported 
214
 on the potential of carbosilane 
dendrimers periphery-functionalized with galabiose (three, 
four, and six galabiose residues) for use as artificial 
inhibitors against Shiga toxins.  
Bhadra et al.
 215
 synthesized PPI dendrimers-coated with 
galactose and investigated the efficiency on delivering 
primaquine phosphate (PP, a liver schizonticide) directly to 
liver cells. The results showed that the coating of PPI 
systems with galactose increases the drug entrapment 
efficiency, prolonged circulation and drug release as 
compared to uncoated PPI delivery systems.  
Agrawal et al. 
216
 demonstrated a method to synthesize 
galactose-coated PLL dendrimers having 
polyethyleneglycol (PEG-1000) as core. This method 
consisted on alternating protection and deprotection steps 
of l-lysine by di-tert-butyl dicarbonate (di-BOC) until the 
formation of peptide dendrimer (G4) took place. Moreover, 
they successfully loaded these macromolecules with 
chloroquine phosphate, which is extensively employed for 
the suppression and treatment of malaria. The 
internalization studies of uncoated and coated drug 
dendrimer formulations in macrophages revealed almost 5 
times reduced phagocytosis due to galactose coating. 
Galactosecoated peptide dendrimers drastically reduced 
haemolytic activity compared to uncoated PLL 
formulation. Haematological data suggested that galactose-
coating strategy decrease immunogenicity as compared to 
uncoated formulations. 
 
DENDRIMER IN THERANOSTICS: DENDRIMER 
BASED COMBINED DIAGNOSIS AND THERAPY 
Recently, a combination of polymer chemistry and imaging 
science approaches has led to the generation of polymer-
based bioimaging probes for the diagnosis and treatment of 
different diseases. The ultimate goal of in vivo imaging is 
to achieve highly sensitive and reliable imaging techniques 
viable for diagnosis in personalized medicine for delivering 
drugs, following their distribution, and monitoring therapy. 
This concept (theranostics) is based on the “find, fight and 
follow” approach
217
. New probes with enhanced 
capabilities and performance should be developed specific 
to nano-imaging techniques. Key research priorities for 
targeted delivery and in vivo imaging should address: (i) 
design of nanostructures with stealth properties that prevent 
them from being opsonised or cleared before reaching the 
target cells, (ii) ability to penetrate into cells and crossover 
biological barriers like the BBB, uptake and recycling of 
nanostructures, (iii) nanocarriers or strategies that 
selectively targets diseased cells, tissues and organs, (iv) 
trans-endocytosis of nanostructures, (v) safety evaluation 
(in vitro/in vivo cytotoxicity, haemocompatibility and 
immunogenicity), in vivo carrier biodistribution, and (vi) 
compatibility with external activation by magnetic field, 
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ultrasound, X-ray, or optics to trigger the therapeutic 
activity. For example, the Kobayashi et al. 
218
 have shown 
that a dendrimer-based magnetic resonance contrast agent 
may be useful for in vivo detection of renal tubular 
damage.  
Rietveld et al. 
219
 developed dendrimers with 
tetrabenzoporphyrin cores for in vivo oxygen imaging. 
While it is promising to incorporate both therapeutic agents 
and molecular-tags on the dendrimers, and improve their 
potency 
210
, the possibility of combining diagnosis and 
therapy in multi-functional dendrimer-based nanosystems 
can allow the early detection, targeting and treatment of 
several diseases. 
Thomas et al. 
221
 have linked PAMAM dendrimers (G5) 
with FITC for tracking, and two different antibodies, 60bca 
and J591, which bind to CD14 and prostrate specific 
membrane antigen (PSMA), respectively. This work 
showed the receptor specificity as the conjugates bound to 
specific antigen expressing cells. Shukla et al. 
222
 
synthesizedPAMAMdendrimers (G5) conjugated to anti-
HER2 monoclonal antibody by tagging the formulation 
with alexaFluor (AF). Flow cytometry studies revealed the 
uptake of conjugate by HER2 expressing cells, while no 
such affinity was found for MCA-207 control cells that did 
not express HER2, in vitro. Another good example of such 
versatile dendrimeric systemswas put forward by Baek and 
Roy 
223
.  
A well-defined multivalent T-antigen (Thomsen-
Friedenrich antigen)-glycoPAMAM dendrimer was 
synthesized, aimed at applications in the detection and 
immunotherapy of carcinomas such as breast cancer. In 
another study 
224
, they synthesized a heterobifunctionalized 
dendritic l-lysine core bearing biotin and T-antigen by 
coupling the thiolated T-antigen derivative to N-
chloroacetylated glycylglycyl llysine dendritic cores. 
According to the literature, the success of entrapping small 
molecules inside the dendrimer depends on the mutual 
properties between the host and the guest molecules. For 
example, Domanski et al. 
225
 reported attempts to entrap 
small fluorescent-probes commonly used to evaluate 
membrane fluidity inside the dendrimer. This work showed 
that 12-(9-anthroyloxy) stearic acid (12-AS), a non-polar 
fatty acid derivative, was successfully incorporated into the 
PAMAM dendrimers cavities, while on the contrary, 1 
(trimethylammoniumphenyl)-6- phenyl-1,3,5 hexatriene p-
toluenesulfonate (TMA-DPH), a amphiphilic salt 
possessing a positive charge, was not. 
Transferrin is a β-globulin (β1-glycoprotein) and facilitates 
the transport of ferric ion (Fe3+) through transferring 
receptors on the plasma membrane. In fact, the use of 
transferrin as a ligand has been explored as a suitable 
delivery system for site-specific delivery to tumors 
226
. PLL 
covalently linked with transferrin for delivery of ONs when 
exposed to human leukemic (HL-60) cells have been stated 
to promote apoptosis to a greater extent as compared to free 
ONs. Another paper 
227
 demonstrated that PEGylated 
poly(cyanoacrylate) nanoparticles conjugated to transferrin 
were effective on the delivery of paclitaxel (PTX), an anti-
tumor drug. PEGylation prevented aggregation of 
nanoparticles and transferrin effectively determined tumor 
site. An innovative study by Choi et al. 
144
 consisted of the 
development of dendrimers conjugated to different 
biofunctional moieties [FITC for imaging, and folic acid 
(FA) for targeting], linked together using complementary 
DNA oligonucleotides to produce clustered molecules for 
targeting tumor cells through folate receptors. This step 
forward allowed obtains both efficient DNA-linked 
dendrimer clusters for intracellular imaging and 
therapeutics, and circumvent the tedious synthesis of 
multiply-functionalized dendrimers.  
Instead of linking oligonucleotides to the dendrimers, 
Majoros et al. 
228
 synthesized amulti-functionalPAMAM 
dendrimer (G5) conjugated with FITC, FA, and PTX. In 
vitro studies have shown that drug-free dendrimer 
conjugates were not cytotoxic even at high concentrations. 
On contrary, drug-loaded dendrimer conjugatesweretoxic 
to both folate receptor-positive and folate receptor-negative 
cells as a result of non-specific binding at concentrations 
around 200 nM. Another good example of PAMAM 
dendrimer-based multi-functional devices (target the desire 
cells, releasing the desired drug and monitoring their 
internalizationfluorescent probe) has been reported by 
Islam et al. 
229
. This group partially acetylated PAMAM 
dendrimers (G5) that were then conjugated with FITC, FA 
and MTX. These were devised to target tumor cells through 
the folate receptor, while releasing an anti-tumor drug 
intracellularly. They showed that HPLC analysis is a 
valuable technique to determine the purity and stability of 
dendrimer-based complexes. 
Yang et al. 
138
synthesized FITC- and biotin-linked 
PAMAM dendrimer (G5) conjugates and investigated their 
ability for targeting cancer cells. The bifunctional 
conjugate (FITC–biotin–dendrimer) exhibited much higher 
internalization by HeLa cells than the conjugate without 
biotin. The uptake was found to be energy- and dose-
dependent, and could be effectively blocked by dendrimer-
conjugated biotin. The results indicate that the 
biocompatible biotindendrimer conjugate can be a 
promising nano-platform for therapy and diagnosis of 
tumors. 
Epidermal growth factor (EGF) is an important factor that 
controls the disposition of neoplastic cells and potentiates 
transcription and proliferation of cells. Human growth 
receptor (HER-2) is amember of EGF family and their 
number is augmented in several tumors 
230
, and hence, it 
provides a potential target for immunotherapeutic agent.  
 
Figure 5: Multifuntional dendrimer 
Nanoparticles having a size in the range 1–10nm have the 
capacity to diffuse into tumor cells. This helps to overcome 
limitations relating to chemotherapy using free drug such 
as poor in vivo/in vitro correlation and overcome other 
possible resistances offered by tumors. In fact, Tomalia 
231
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has also proposed the use of ~5nm sodium salt-PAMAM 
dendrimers (G4.5) nanoparticles possessing a 1,4-
diaminobutanecore, as multi-purpose nanodevices for 
oncology drug delivery and diagnostic MRI contrast 
agents. 
 
OTHER BIOMEDICAL APPLICATION OF 
DENDRIMERS 
1. Dendrimers in Tissue Engineering:  
The aim of tissue engineering applications is for the 
encapsulated cells to regenerate native extracellular matrix 
(ECM) and eventually replace the scaffold altogether. 
Therefore, the scaffold must biodegrade at a rate that 
complements the biosynthesis of new ECM. 
Polymeric scaffold compositions can be divided into two 
main categories: natural and synthetic. Natural scaffolds 
are constructed from proteins, carbohydrates, or 
glycoproteins. Collagen is the most commonly used protein 
for scaffold construction 
232
. Fibrin is another protein used 
for scaffold construction due to its ability to assemble into 
mesh-like networks. Hyaluronic acid and chondroitin 
sulfate are key structural components and have been used 
extensively as tissue engineering scaffolds. Carbohydrates 
such as alginate 
233
, dextran 
234
, and chitosan 
235
 are also 
used as scaffold materials due to their ability to form 
hydrated networks. The synthetic linear polymers, such as 
poly(lactic acid) (PLA), poly(glycolic acid) (PGA), 
poly(caprolactone) (PCL), and poly(ethylene glycol) (PEG) 
have also been used extensively as scaffold materials 
236
. 
Kim et al. 
237
 also investigated the response of human 
epithelial cells to dendrimer-immobilized substrates, with 
or without D-glucose displayed as a terminal ligand. When 
the topographic surface possessed a roughness of 4 nm, 
epithelial cells cultured on naked dendrimer surface 
without D-glucose were somewhat stretched in their 
morphology compared with those on a non-modified plain 
surface. However, for the roughness values higher than 
4nm cell stretching was inhibited, thus resulting in the 
predominance of round-shaped cells. The change in cell 
morphology was quite evident on the surfaces with D-
glucose-displayed dendrimers. Fluorescence microscopic 
observation showed that when the roughness value 
increased up to 4.5nmon these surfaces, an enhancement of 
cell stretching occurs. These results suggested that surface 
roughness and D-glucose display induce changes in cellular 
morphology caused by the cytoskeleton formation 
accompanied by marked cell elongation. Therefore, this 
study demonstrated that dendrimer surfaces can offer a 
promising design for optimizing cells culture conditions. 
Benhabbour et al. 
238
, demonstrated that cells showed a 
greater affinity for the dendronized surfaces as compared to 
Au surfaces (control). Moreover, in vitro cell culture 
studies with mouse 3T3 fibroblasts showed that cell 
attachment was diminished for the PEG-grafted Au 
surfaces as compared to the control Au and G1–G4 
dendronized surfaces. These results showed that 
dendronized surfaces presenting a large number of 
hydroxyl groups can be a reliable alternative to the use of 
peptides to promote cell-adhesion and proliferation. 
2. Dendrimers in Cell Repair:  
Intact extracellular matrices (ECMs) have demonstrated 
potential as biomaterials in various tissue engineering and 
clinical applications 
239
. These ECM scaffolds provide a 
natural three-dimensional support to aid the initial 
mechanical requirements necessary to support damaged or 
excised tissue 
240
. In addition, ECM provides vital 
biological cues for cellular recognition which is essential 
for initial cellular attachment, subsequent cellular 
differentiation, in-growth of vascular networks, and 
secretion of new ECM requisite for eventual scaffold 
remodeling and tissue regeneration. Dendrimer works as a 
linker to the scaffold and as a carrier of bioactive 
molecules. The dense functional groups terminated on 
surface of dendrimers can react with intrinsic functional 
groups in protein-based scaffolds to form covalent binding. 
Conveniently in this way, scaffold stability can also be 
tailored by controlling the extent of cross-linking, which 
has the benefit of extending their in vivo life 
241
.  
Availability of multiple functional groups effectively 
amplifies the number of sites available for conjugation with 
exogenous bioactive molecules. For example, Chan et al. 
242
 used generation 1 polyamidoamine (G1 
PAMAM)dendrimer as amodel dendrimer and incorporated 
into cholecyst-derived extracellular matrix (CEM), a novel 
intact extracellular matrix derived from the perimuscular 
subserosal connective tissue of porcine cholecysts 
developed in their laboratory 
243
. They observed the 
incorporation of varied feed concentrations of PAMAM 
dendrimer in CEM using the EDC/NHS cross-linking 
system resulted in covalent binding of PAMAM on CEM. 
Varied degrees of cross-linking, improved stability of CEM 
to enzymatic degradation, increased amine functional 
groups useful in tethering bioactive agents, maintenance of 
tensile strength but increased flexibility of scaffold, and 
preservation of the ability of DENCEM to support cells in 
vitro were observed.  
On the other hand, Boduch-Lee et al. 
244
 showed the design 
and synthesis of star polycaprolactone-hydroxyapatite films 
for use as a biodegradable matrix for bone tissue 
engineering. They used a hybrid scaffold composed of 
poly(caprolactone) (PCL) chains conjugated to a 
poly(Llysine) dendritic core to fabricate an HA-composite 
for in vitro bone regeneration. The effect of these scaffolds 
was evaluated in the cell line MG-63. They observed that 
the dendrimer-PCL HA hybrid performed much better than 
linear PCL, suggesting that the dendritic architecture 
presents advantages over linear polymers for the purposes 
of in vitro bone cell growth and adhesion over 24 hours. 
3. Dendrimers in Blood Substitution 
Dendrimers are also being investigated for use as blood 
substitutes. Their steric bulk surrounding a heme-mimetic 
centre significantly slows degradation compared to free 
heme
245,246
 and prevents the cytotoxicity exhibited by free 
heme. 
4. Cosmetics and personal care applications 
Because of their excellent carrier properties, dendrimers 
have utility in cosmetics and personal care products such as 
hair-styling gels, shampoos, sunscreens, and anti-acne 
products. Cosmetic compositions comprising hydroxyl-
functionalized dendritic macromolecules are described in a 
patent filed by Unilever's Home & Personal Care division 
for application in a hair-styling spray, gel, or mousse 
formulation 
247
. The dendritic macromolecules indicated for 
the hairstyling application in this patent use the polyhydric 
polyester alcohol or hyperbranched polyol functionalized 
groups. Another patent filed by L'Oreal described terminal 
Dhakar et al                                       Journal of Drug Delivery & Therapeutics. 2016; 6(1):67-92 86 
© 2011-15, JDDT. All Rights Reserved                                                   ISSN: 2250-1177                                             CODEN (USA): JDDTAO 
hydroxyl functional group polyester dendritic 
macromolecules in combination with film-forming 
polymers for use in cosmetic and dermatological products 
intended for application to the skin, keratinous fibers, nails, 
or mucous membranes 
248
. Such a combination of a film-
forming polymer with a dendritic polymer allowed the 
inventors to develop a low-viscosity product that was easily 
applied to the intended topical skin site and that formed a 
dry film capable of being peeled-off after the application 
period. This property allowed for superior cosmetic product 
performance and ease of use. Here, the unique ability of 
dendrimers to form lower viscosity solutions was used to 
the advantage of the formulation chemist. 
Surface modifications of dendrimers have been used as 
molecular-carrying systems. For example, dendrimers 
containing at least one free amino group have been used to 
carry anti-acne agents in a patent filed by Revlon consumer 
products 
249
. A keratolytic or anti-acne agent was 
complexed with a carrying molecule such as a dendrimer 
containing free amino groups to obtain cosmetically 
acceptable formulations for treatment of acne vulgaris. In 
another example of a dendrimer-molecule conjugate 
system, coupling of aminobutadiene with an amine-rich 
dendritic molecule provided advantageous UV-absorbing 
capabilities to the final product 
250
.  
This high-molecular-weight dendrimer-aminobutadiene-
complexed molecule allowed ease in formulating a clear 
sunscreen composition without developing high-viscosity 
gels, which in turn provided ease of application to the skin. 
Because of the high molecular weight of the resulting 
molecule, it was nonpenetrating into the skin, which would 
minimize risk of irritation or sensitization reactions while 
acting as a UV-light absorber when applied on the skin's 
surface. In another application, amine-terminated cationic 
dendrimers have been used in personal-care cleansing 
compositions as mildness agents 
251
.  
Linear cationic polymers used as mildness agents usually 
precipitate in the presence of anionic surfactants, which 
reduce their lathering, skin conditioning, or cleansing 
effects. Dendrimers, on the other hand, are capable of 
interacting favorably and can bind with anionic surfactants 
in the composition to remain dispersed in salt solutions. 
This interaction of cationic dendrimers with skin-irritating 
anionic surfactants could potentially be used by the 
personal care chemist for reducing the skin irritation 
potential of cosmetic formulations containing harsh anionic 
surfactants. 
US patent 6,001,342 described the use of dendrimers 
containing terminal amine groups such as 
polyamidoamines (Starburst, Starpharma) in antiperspirant 
deodorant compositions to reduce underarm odors 
252
. 
Some of the selected dendrimers were found to have odor-
absorbing properties and were claimed as deodorant active 
agents. These dendrimers could be formulated in water-
based compositions in appreciable amounts and were found 
to be nontoxic or nonirritating.  
Novel self-tanning cosmetic compositions described in US 
Patent 6,399,048 contain amine-terminal group dendrimers 
in addition to a tanning agent 
253
. The dendrimer-containing 
composition was shown to have improved efficacy and 
self-tanning activity on application to skin. Dendrimer-
containing compositions in this case were shown to 
increase the intensity and quality of skin coloration 
produced, as well as providing a shade that was closer to a 
natural tan. As shown in various examples of dendrimer 
application, the rich functional surface groups and the 
viscosity characteristics of dendrimers have been used to 
add unique claims and product differentiation to personal-
care products. 
 
CONCLUSION 
The objective of this review was to summarize the unique 
properties and advantages that dendrimers offer along with 
its application in field of drug delivery, diagnosis and 
therapy.   
Dendrimers can work as a useful tool for optimizing drug 
delivery of such problematic drugs. Although the 
application of dendrimers in the field of drug, gene, and 
vaccine delivery is in its infancy, dendrimers offer several 
attractive features, including the control one has over the 
primary nature of the system. They provide a platform for 
the attachment of drugs or genes and their release through 
several mechanisms.  
The main conclusion is that the high level of control over 
the architecture of dendrimer, their shape, branching length 
and density, their surface functionality and interior void 
space (porosity) and so on makes dendrimer ideal carriers 
for the various applications like drug delivery, therapeutic 
and diagnostic agent. Poor solubility, bioavailability and 
permeability biocompatibility and toxicity can be overcome 
by use it. 
The high density of surface groups allows attachment of 
targeting groups as well as groups that modify the solution 
behaviour or toxicity of dendrimers. Bioactive agents might 
be encapsulated into the interior, physically adsorbed or 
chemically attached to the dendrimer surface, with many 
options for tailoring vector properties to the specific needs 
of the active material and its therapeutic applications. 
Furthermore, the ability to select nanoscale-sized vectors 
with mathematically determined numbers of surface groups 
and welldefined interior void space allows systematic size 
adjustments to determine excretionary pathwayswhile 
producing optimal ratios of targeting moieties, therapy and 
surface groups required in combination with desired 
solution behavior, excretionary pathway and acceptable 
toxicity margins. Finally, certain anionic surface-modified 
dendrimers are proving to function as safe and effective 
topical nanopharmaceuticals against HIV and genital 
herpes. 
Hopefully, this review of dendrimer-based medical 
applications clearly illustrates the potential of this new 
‘fourth architectural class of polymers’ and reaffirms an 
even higher level of optimism for the future role of 
dendrimers in the drug delivery, diagnosis and therapy. 
 
FUTURE PROSPECTS 
Dendrimeric polymers are very important and convenient 
for drugs delivery, diagnosis and therapy. In order to be 
effective, dendrimer-based products should be based on 
scientific evidence for their usefulness and must be easier 
to translate from laboratory to the clinic, in other words be 
quality-controlable, cost-effective and sustainable. 
Literature review of biomedical applications of the 
dendrimers clearly illustrate the potential of this new fourth 
architectural class of polymers and substantiate the high 
optimism for the future of dendrimers in drug delivery, 
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diagnosis and therapy. Scientists have explored the use of 
dendrimers for various applications in oral, transdermal, 
ophthalmic, and gene delivery. Although dendrimer drug 
delivery requires attention to certain manufacturing and 
biological considerations to be successful. 
Besides drug delivery, dendrimers have been found to have 
a great emphasis in gene delivery, boron neutron capture 
therapy, PDT and as magnetic resonance imaging contrast 
agents. The use of dendrimers in the clinic has still not 
reached the success of linear polymers and several 
applications remain to be explored for its industrial as well 
as biomedical applications. With improved synthesis, 
further understandings of their unique characteristics and 
recognition of new applications, dendrimers will become 
promising candidates for further exploitation in drug 
discovery and clinical applications. Boosting of 
commercial applications of dendrimer technology will 
provide strength for its usefulness in future. 
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Abbreviations: 2-AS, 12-(9-anthroyloxy) stearic acid; 2-D, 
two-dimensional; 3-D, three-dimensional; 3-TC, 
lamivudine; Ac, acetylated; AChE, acetylcholinesterase; 
AF, alexaFluor; AFM, atomic force microscopy; ATRP, 
atom transfer radical polymerization; b-FGF, basic 
fibroblast growth factor; BAPTA-AM, 1,2-bis-(o-
aminophenoxy) ethane-N,N,N’,N’,-tetraacetic acid-
acetoxymethyl ester; ˇ-CD, ˇ-cyclodextrin; BBB, blood 
brain barrier; BMVEC, brain micro-vessel endothelial 
cells; BNTC, boron neutron capture therapy; BSA, bovine 
serum albumin; CLB, chlorambucil; CED, convection 
enhanced delivery; CMCht, carboxymethylchitosan; 
CMCht/PAMAM, carboxymethylchitosan/poly 
(amidoamine); DCC, dicyclohexylcarbodiimide; Dex, 
dexamethasone; DDS, drug delivery system; di-BOC, di-
tert-butyl dicarbonate; DOPE, 1,2-dioleyl-3-
phosphatidylethanolamine; DOTAP, N-(1-(2,3-dio-
leoyloxy) propyl)-N,N,N-trimethyl ammonium 
methylsulfate; Dox, doxorubicin; EBV, Epstein Barr virus; 
ECM, extracellular matrix; EG, ethylene glycol; EGF, 
epidermal growth factor; EGFP, green fluorescent protein; 
ENFET, enzyme field-effect transistor; EPR, electron 
paramagnetic resonance; FA, folic acid; FITC, fluorescein 
isothiocyanate; G, generation number; GAGs, 
glycosaminoglycans; GLUT 1, glucose transporter; GOX, 
glucose oxidase; HA, Hyaluronic acid; HAp, 
hydroxyapatite; HAS, human serum albumin; HBP, 
hyperbranched polymer; HER-2, human growth receptor; 
HMGB1, high mobility group box 1 plasmid; HSGP, 
heparin or heparan sulfate proteoglycan; i.p., 
intraperitoneal; i.t., intratumoral; LCST, lower critical 
solution temperature; LH, light-harvesting; MA, 
methacrylate; MAPs, multiple antigen peptides; Man, 
mannose; Mn, number-average molecular weight; Mo/Mac, 
monocyte/macrophages; MPPI, poly(propyleneimine); 
MRI, magnetic resonance imaging; MS, multiple sclerosis; 
Mw,weight-average molecular weight,Mw/Mn 
polydispersity index; NaHA, sodium 
hyaluronate;NMR,nuclear magnetic resonance; OEI, 
oligoethylenimine; OG, oregon green; ONs, antisense 
oligonucleotides; PAMAM, poly(amidoamine); PAH, p-
aminohippuric acid; PCI, photochemical-internalization; 
PDMA, poly(N,N-dimethylaminoethyl methacrylate); 
PEG-DA, poly(ethylene glycol)-dialdehyde; PEI, 
poly(ethyleneimine); PEPE, polyether-copolyester; PETIM, 
poly(propyl ether imine); PLGSA, poly(glycerol-succinic 
acid); PLL, poly-(l-lysine); PNIPAAM, poly(N-
isopropylacrylamide); PP, primaquine phosphate; PPI, 
poly(propyleneimine); PrPSc, protease-resistant isoform of 
the prion protein; PSMA, prostrate specific membrane 
antigen; PTX, paclitaxel; RAFT, reversible addition-
fragmentation transfer; RGD, Arg-Gly-Asp peptides; ROS, 
reactive oxygen species; SA, sulfasalazine; SEM, scanning 
electron microscopy; shRNA, small hairpin RNA; t-BOC, 
N-tert-butoxycarbonyl; TE, tissue engineering; ThT, 
thioflavin T; TIMP, tissue inhibitors of metalloproteinases; 
TMA-DPH, 1 (trimethylammoniumphenyl)-6-phenyl-1,3,5 
hexatriene p-toluenesulfonate; VEGF, vascular endothelial 
growth factor. 
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